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 PROFORMA 
Name:       Age: 
Sex:        Occupation: 
H/O smoking:                           
No of cigarettes/day:    For how many years: 
H/O alcohol intake:  
Nil/occasionally/weekly/monthly. For how many years: 
Regular exercise:   
Time spent/day:    For how many years: 
Diet:             Vegetarian/Non vegetarian. 
Duration of sleep/day: 
Stress score as per PSS 10:  
Duration of service: 
Working hours/day: 
 
 
 
            Duration           On treatment 
 
H/O Diabetes:   
H/O Hypertension:   
H/O Hyperlipidemia: 
  
  
 H/O Angina:  
Family H/O Diabetes/Hypertension/Hyperlipedemia: 
Medications if any: 
Anthropometric measurements: 
Ht (cm):                  Wt (kg):             BMI(kg/m
2
): 
 Waist circumference (cm):  Waist hip ratio: 
General Examination: 
Consciousness:   Orientation: 
Comfortable at rest:  Pallor: 
Cyanosis:    Clubbing: 
Jaundice:    Pedal oedema: 
Thoracic/Spine deformity: 
JVP:     Generalized Lymphadenopathy: 
Temperature (
0
F):   Respiratory rate/min: 
Pulse rate/min:   Blood pressure (mmHg): 
CARDIOVASCULAR SYSTEM: 
 
RESPIRATORY SYSTEM : 
 
ABDOMEN                                : 
 
CENTRAL NERVOUS SYSTEM: 
 BIOCHEMICAL MEASUREMENTS:  
Fasting blood glucose level (mg/dl): 
Serum triglycerides (mg/dl): 
Serum HDL (mg/dl): 
மருத்துவப் பரிச ோதனை முனைகனைப் பற்ைி மருத்துவரிடம் ததரிந்து 
தகோண்சடன். இதனை சமற்தகோள்ை நோன் முழுமைதுடன்  ம்மதிக்கிசைன். 
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1. fle;j khjk; Vjpu;ghuhj tpjkhf ele;j rk;gtq;fshy ;vj;jid jlitfs; 
ftiyAw;wPu;fs;? 
 
 
2. fle;j khjk; cq;fs; tho;f;ifapYs;s Kf;fpakhd tplaq;fis cq;fshy; 
fl;Lg;gLj;j Kbahky; ,Ue;jjhf vj;jid jlitfs; czu;e;jPu;fs;? 
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INTRODUCTION 
Metabolic syndrome is a group of anthropological and biochemical 
abnormalities that predispose a person to cardiovascular disease, Type 2 Diabetes 
Mellitus and stroke. It is a group of interrelated abnormalities namely central 
obesity, raised blood pressure, high triglycerides, decreased levels of high-density 
lipoprotein cholesterol and elevated fasting blood glucose levels. 
AIMS AND OBJECTIVES 
To evaluate the occurrence of metabolic syndrome among occupational 
drivers and to assess the contributors of metabolic syndrome like physical activity, 
duration of driving, smoking, alcohol intake and stress level among occupational 
drivers. 
METERIALS AND METHODS: 
It is a cross sectional  study, conducted in Jeyavilas bus depot, Madurai 
among 100 randomly selected male occupational drivers of age group between 25 
to 60 years males who were drivers by occupation for > 5 years with minimum 8 
hours of driving per day. 
         The study was initiated with the  approval  of  Institutional ethical committee, 
Madurai Medical College, Madurai. After getting informed, written consent, a 
questionnaire is given for collecting the history. Basic cardiovascular and 
anthropometric measurements are taken. Under strict aseptic precautions a blood 
sample of 3ml is collected after overnight fasting for at least 8 hours. Fasting blood 
glucose level, serum triglycerides and HDL analysis to be carried out using 
standard techniques. 
RESULTS: 
Statistical comparison between the measured variables carried out using Chi- 
Square test revealed significant association between increased BMI, physical 
inactivity, stress, smoking, increased duration of service with occurrence of 
metabolic syndrome. 
CONCLUSION: 
Drivers sit for long hours and walk less compared to the general public. In 
addition, physical activity involvement and physical demands during the driving 
are usually limited and insufficient to maintain physical fitness. The most effective 
measures to improve insulin sensitivity in metabolic syndrome affected individuals   
are exercise and weight loss. Both  modalities  are  effective   and  can  be  additive   
in  their  ability to improve  insulin action.  Smokers should be advised to quit 
smoking. Change in the lifestyle is the best way in the prevention of metabolic  
syndrome. 
 
Key words: 
Metabolic syndrome, obesity, blood pressure, triglycerides, high-density 
lipoprotein  cholesterol, fasting blood glucose, occupational drivers. 
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INTRODUCTION 
The metabolic syndrome has received a great deal of attention in the 
last few decades. Metabolic syndrome is a group of anthropological and 
biochemical abnormalities that predispose a person to cardiovascular  
disease, Type 2 Diabetes Mellitus and stroke. It is a group of interrelated 
abnormalities namely central obesity, raised blood pressure, high 
triglycerides, decreased levels of high-density lipoprotein (HDL) cholesterol 
and elevated fasting glucose levels. This is a common metabolic disorder 
which increases in prevalence as the population becomes more obese.  
Metabolic syndrome is associated with a 2-fold risk of cardiovascular  
disease and a 5-fold risk of  diabetes. Persons with metabolic syndrome have 
a 30%–40% probability of developing Type 2 Diabetes Mellitus and/or 
cardiovascular disease within 20 years and it depends on the number of 
components present. 
The World Health Organization has anticipated India as the diabetic 
capital of the world. At present the total  number of   people affected   with  
diabetes worldwide is almost 150 million, with affected population of 25 
million in India alone. By 2030, it is predicted that the number of people 
diagnosed with  diabetes will reach about 366 million world wide, with the     
maximum  number of  cases  in  India. 
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Throughout the world, cardiovascular disease has  become  the most 
common cause of mortality. In 1990, the probable deaths due to 
cardiovascular disease was around 5.3 millions. At present, 8-9 millions,     
from the developing countries were affected with cardiovascular disease. By 
the year 2015, cardiovascular disease will be the most important contributor  
of mortality in India. 
According to recent data in the Journal of the American Medical 
Association, it is estimated that 47 million people have metabolic syndrome. 
The incidence of this syndrome rises progressively as individuals begin to 
age, reaching a peak between the ages of 60 and 69 years and the prevalence 
increasing from 10% in the 30–39-year age group to 45% in the 60–69-year 
age group. 
Based on data from the National Health and Nutrition Examination 
Survey (NHANES) III (1988-1994), nearly 24% of U.S. adults aged 20 
years or older have metabolic syndrome. This rate has been raised to 27% in 
NHANES 1999-2000 and 34% in NHANES 2003-2006.  
          Similar to the western countries, the prevalence of metabolic 
syndrome  in developing countries is also promptly increasing. A study by 
Misra A and Khurana L in 2008 showed that the situation is similar in  
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India with the recent data suggesting that upto one fourth and one third 
Indian adult population suffer from metabolic syndrome. Chow et al., 2008 
established a prevalence of metabolic syndrome of 26.9% in males and 
18.4% in females in Southern India. This increase is observed regardless of 
the criteria used and it reflects the transition from a traditional to a Western 
lifestyle. These changes cause significant effects on body composition often 
causing a rise in BMI, generalized and abdominal obesity, an increase in 
dyslipidemia and Type 2 Diabetes Mellitus. Intrauterine and early postnatal 
undernutrition have been suggested as one of the important causes of 
development of metabolic syndrome Misra A et al., 2008. In general, the 
International Diabetes Federation estimates that one-quarter of the world's 
adult population has metabolic syndrome (IDF 2006). 
The study conducted by Rajeev Gupta et al., 2012 in  Jaipur, showed   
the prevalence of  metabolic syndrome was 25.1% in males and 22%  in 
females in urban  population. Occurrence of diabetes  and hypertension  was  
more in  men, low HDL cholesterol levels and abdominal  obesity  was more 
in women. 
It is obvious that occupational drivers are associated with considerable 
changes in lifestyle habits. Occupational drivers are prone to develop 
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metabolic syndrome because their working environment is characterized by 
numerous stress factors such as lack of physical activity due to working in a 
stationary position, disruption in diet and irregular sleep pattern.The related 
impacts are not only harmful for driver's health but also may endanger 
others, because any health issue that affects drivers may result in an 
increased risk for road accidents. The aim of the present study is to evaluate 
the contributors of metabolic syndrome among occupational drivers in 
Madurai district. 
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AIMS AND OBJECTIVES 
 
1. To assess the contributors of metabolic syndrome among occupational 
drivers. 
2. To evaluate the occurrence of metabolic syndrome among 
occupational drivers. 
3.  To study the correlation of BMI, physical activity and metabolic 
syndrome. 
4. To assess the relationship between duration of driving with 
occurrence of metabolic syndrome. 
5. To study the effect of smoking and alcohol intake with occurrence of 
metabolic syndrome.    
6. To analyze the link between stress level with occurrence of metabolic   
syndrome.    
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REVIEW OF LITERATURE 
HISTORY OF METABOLIC SYNDROME 
          In 1920s, it   was   proposed   that diabetes  was  associated  with  
various   risk   factors   but   the   term   "metabolic syndrome"   was     first    
used  since   1950 and    only    in    late   1970   onwards,  it   came   into  
common    practice.   
           In 1947,Dr. Jean Vague, the Marseilles physician, found  that      
abdominal obesity predisposed to  gout, atherosclerosis, diabetes and calculi. 
Crepaldi, Avogaro and   their   colleagues    performed   a study   on     
obese patients with marked hypertriglyceridemia and diabetes. All of them 
were put on a low carbohydrate diet and they showed improvement.  
In 1988, Gerald M.Reaven, an endocrinologist physician from 
Stanford University was the one who interpreted the association of diabetes, 
obesity, dyslipidemia and arterial hypertension by their pathogenic 
relationship with the peripheral insulin-resistance. He named this association 
“X syndrome”, the name underlining the doubtfulness of emitting an 
apparently new concept. The insulin resistance and the compensatory 
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hyperinsulinism were associated with each component of the metabolic 
syndrome, proposing thus a physio-pathological connection between them. 
             The X syndrome    was    renamed   as   “The Deadly Quartet”   by    
Kaplan in 1989. It was again renamed as “The insulin resistance 
syndrome”   in   1992. 
 Afterwards, it was found out that the spectrum of metabolic 
disturbances is greater. Zimmet expressed the “plus X syndrome” 
establishing  the association with hyperuricaemia, sedentariness and old age. 
            On 1998, in the Chronic Fatigue Syndrome Conference, Dr Allen  E.  
Gale, a physician, presented  a case report  in  Australia   and  proposed  the  
term   CHAOS,  which  is  an abbreviation for Coronary artery disease, 
Hypertension, Atherosclerosis, Obesity and Stroke. 
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CRITERIA FOR METABOLIC SYNDROME 
At present, four sets of criteria are most commonly used  for defining 
the metabolic syndrome. 
 
WHO---CRITERIA: 
The WHO definition,1998was the first to link the key components of 
insulin resistance, obesity, dyslipidemia and hypertension. The definition 
mandates the presence of insulin resistance, in addition any two of the 
following: 
 Central obesity-Body mass index >30 kg/m2 or  
      Waist:Hip ratio> 0.85  (female),  > 0.90 (male) 
 Dyslipidaemia-HDL  ≤ 0.9 mmol/L (male) ≤ 1.0 mmol/L (female)    
     Triglycerides ≥ 1.695 mmol/L. 
 Blood pressure- ≥ 140/90 mmHg. 
 Microalbuminuria-albumin : creatinine  ratio ≥  30 mg/g  or   
 urinary albumin   excretion   ratio  ≥ 20 µg/min.   
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NCEP:ATPIII 2001-CRITERIA: 
In 2001, the National Cholesterol Education Programme (NCEP) Adult 
Treatment Panel III (ATP III) framed a definition for the metabolic 
syndrome (National Cholesterol Education Programme, 2002), it was 
updated by the American Heart Association and the National Heart Lung 
and Blood Institute in 2005 Grundy et al., 2004. According to it, metabolic 
syndrome is present if three or more of the following five criteria are met:  
 Blood pressure: systolic  ≥ 130 or diastolic ≥ 85 mmHg . 
 Fasting triglyceride (TG) level  : Triglycerides ≥150mg/dl. 
 Waist circumference : >40 inches (male), >35 inches (female) 
 Fasting plasma glucose:  ≥ 110mg/dl. 
 Fasting HDL level: <50  mg/dl (male),  < 40 mg/dl   (female).   
It is one of the most widely used criteria of metabolic syndrome. It 
includes the key features such as hyperglycemia/insulin resistance, visceral 
obesity, atherogenic dyslipidemia and hypertension. It makes use of the 
measurements and laboratory results which would be readily available to 
physicians, allowing its clinical and epidemiological application. 
Importantly, it does not necessitate that any specific criterion be met.  
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IDF-CRITERIA : 
In 2005, the International Diabetes Foundation (IDF) has put out a new 
criteria for metabolic syndrome Zimmet et al., 2007.  
The IDF definition of the metabolic syndrome is.
 
Central obesity PLUS any two of the following: 
 Elevated fasting plasma glucose (FPG): >100  mg/dl or a known   
case of Type 2 Diabetes Mellitus. 
 Fasting triglycerides >150mg/dl or specific medication. 
 HDL < 50 mg/dl and < 40 mg/dl for women and men respectively. 
 Blood pressure >85 mmHg diastolic or >130 mmHg systolic or a 
known case of hypertension. 
Waist circumference with geography – specific values for  defining Central 
obesity. 
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Central Adiposity   by  IDF Criteria: 
Men Women Ethnicity 
≥85cm  ≥ 90cm           Japanese. 
≥90cm    ≥80cm          Central American, Chinese and South Asian. 
≥94cm   ≥80cm            Middle  Eastern, Eastern, Europid and 
       Sub-Saharan  African. 
The WHO and IDF definitions are limited by their applicability and 
clinical acceptability. The most accepted definition is the NCEP-ATP III one 
because of his simplicity. 
MODIFIED NCEP ATPIII- CRITERIA FOR THE METABOLIC 
SYNDROME: 
In 2005, the American Heart Association and the National Heart, Lung 
and Blood Institute (AHA / NHLBI) conducted a revision of the metabolic 
syndrome diagnostic criteria - modified  NCEP ATPIII criteria. 
The important changes in the modified AHA/NHLBI definition, ATPIII 
2005Grundy et al., 2005 include: 
12 
 
(i) Addressing the ethnic-specific variation in central obesity by using the 
WHO recommendations for waist circumference: 90 cm in Asian men, 80 
cm in Asian women. 
(ii) Decreasing the threshold for impaired fasting glucose to  ≥ 100mg/dl, in 
accordance with the American Diabetes Association (ADA) revised 
definition Genuth et al., 2003. 
(iii) Permitting individual components to be counted abnormal if patients are 
receiving drug treatment for these conditions. 
By making these difference the predictive ability to diagnose 
metabolic syndrome has become highest with modified NCEP-ATP III. 
SIGNS AND SYMPTOMS 
 Central obesity (otherwise referred as visceral, apple-shaped or       
android type of adiposity). 
 Elevated blood pressure. 
 Fasting hyperglycemia- impaired fasting glucose or impaired glucose 
tolerance, Type 2 Diabetes Mellitus. 
 Elevated triglycerides. 
 Reduced High-density lipoprotein cholesterol. 
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PATHOPHYSIOLOGY 
Metabolic Syndrome is the result of complex interplay between 
genetic and environmental factors. Understanding in detail about the 
pathophysiology of this syndrome is important  in order to identify people at 
risk of developing cardiovascular disease which will help in early 
intervention for prevention Lann D, LeRoith D 2007.  
Functional aberrations seen in metabolic Syndrome are: 
1. Insulin resistance 
2. Dyslipidemia 
3. Central obesity 
4. Hypertension  
5. Proinflammatory state 
6. Prothrombotic state. 
1.INSULIN RESISTANCE  
The metabolic syndrome is also known as the insulin resistance 
syndrome, since it has been postulated that insulin resistance is the key 
mechanism responsible for the metabolic abnormalities of the syndrome 
Lann D, LeRoith D 2007. Insulin resistance has been defined as a defect in 
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insulin action that results in hyperinsulinaemia which is necessary to sustain 
the euglycaemic state. Concept of insulin resistance provides a conceptual 
framework which places a substantial number of apparently unrelated 
biological events into a pathophysiological construct. 
Insulin is synthesized by the pancreas in response to hyperglycemia and it 
stimulates glucose use differently in different tissues.  
Effect of insulin on various tissues are: 
 In the skeletal muscle and adipose tissue               stimulates glucose 
uptake by translocation of the GLUT4 glucose transporter to the 
surface of the cell.  
 In the skeletal muscle and liver             stimulates the synthesis of 
glycogen from glucose and they inhibits glycogenolysis.  
 In the liver          decreases hepatic gluconeogenesis, thus preventing 
an influx of more glucose into the bloodstream.  
 In adipose tissue             inhibits fat breakdown and stimulates glucose 
uptake.  
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The net effect of all of these mechanism is to  
1.Increase glucose uptake,  
2.Reduce circulating glucose levels and  
3.Increase the conversion of glucose into the storage molecules, glycogen or 
fat Kim et al., 2006.  
Normally fasting insulin level is between 5-15µU/ml. But in Insulin 
resistance it is about >15 µU/ml. In insulin resistance, adipose tissue, muscle 
and liver do not respond to insulin, hence the blood glucose levels remain 
high, leading to pathology.  
When insulin signalling occurs, insulin binds to the insulin receptor, 
which is a ligand-activated tyrosine kinase. Binding of insulin produces 
tyrosine phosphorylation of downstream substrates and activation of two 
parallel pathways:  
1.The phosphoinositide 3-kinase (PI3K) pathway and  
2.The mitogen-activated protein (MAP) kinase pathway.  
1. Activation of  PI3K, leads to activation of the 3-phosphoinositide-
dependent protein kinase 1 (PDK1) kinase and Akt kinase. The PI3K-Akt 
pathway help in many of the metabolic effects of insulin. 
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 In vascular endothelial cells, it causes phosphorylation and 
activation of endothelial nitric oxide synthase (eNOS).  
 In skeletal muscle and adipose tissue, it stimulates 
translocation of GLUT4 glucose transporter to the surface of 
the cell leading to increased glucose uptake. 
2. Similarly, activation of  MAP kinase pathway is responsible for 
 Endothelin-1(ET-1) production which leads to vasoconstriction. 
 Expression of the vascular cell adhesion molecules (VCAM-1) 
and E-selectin resulting in more leukocyte-endothelial 
interactions and 
 Mitogenic action on vascular smooth muscle cells. 
In insulin resistance, the PI3K-Akt pathway is affected, while the 
MAP kinase pathway remains unaffected. This leads to a change in the 
balance between these two parallel pathways.  
Since PI3K-Akt pathway is affected, it leads to a decrease in 
endothelial nitric oxide (NO) production causing endothelial dysfunction. 
This also leads to a reduction in GLUT4 translocation which leads to 
decreased glucose uptake in skeletal muscle and fat. By contrast, the MAP 
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kinase pathway is unaffected, hence there is a continued production of ET-1, 
expression of VCAM-1 and mitogenic stimulus to vascular smooth muscle 
cells. By these mechanisms, insulin resistance results in vascular 
abnormalities which predisposes to atherosclerosis. 
Insulin increases local blood flow in tissues by the activation of eNOS 
Kim et al., 2006; Jonk et al., 2007. This leads to two separable effects 
1. Capillary recruitment occurs within minutes. 
2. Dilation of the larger-resistance vessels increases overall 
perfusion between 30 minutes and 2 hours.  
These two  effects contribute to vasodilation and increased delivery of 
glucose and insulin to tissues. The vascular effects of insulin couples with 
glucose homeostasis and contribute to glucose metabolism at physiological 
concentrations of insulin. Thus, insulin acts coordinately on peripheral 
glucose use, vascular tone and blood flow. Therefore common mechanisms 
that contribute to insulin resistance can also cause vascular dysfunction, 
hyperglycemia, etc. 
The linked concepts of metabolic syndrome helped us by providing a 
simple construct to characterize many types of patients who the physicians 
see daily and to help them identify people at risk Yehuda H 2009.  
18 
 
2.DYSLIPIDEMIA 
 A major contributor to the development of insulin resistance is an 
excess of free fatty acids (FFA), released from an expanded adipose tissue. 
Excessive release of free fatty acids from adipose tissue into plasma and 
increased plasma free fatty acids concentration can impair insulin-mediated 
glucose uptake in muscle and suppress hepatic glucose production. Increased 
level of circulating glucose increases insulin secretion resulting in 
hyperinsulinemia. 
In the liver, FFAs acts as a substrate for synthesis of triglycerides 
(TGs). FFAs also stabilize the synthesis of apoB, which is a chief lipoprotein 
of very-low-density lipoprotein (VLDL) particles, this results in increased 
production of VLDL. VLDL in turn is metabolized to remnant lipoproteins 
and small dense LDL, both of which can stimulate atheroma formation.  
The TGs in VLDL are transferred to HDL by the cholesterol ester 
transport protein (CETP) in exchange for cholesteryl esters. This results in 
TG-enriched HDL and cholesteryl ester-enriched VLDL particles. The TG-
enriched HDL is a better substrate for hepatic lipase, hence it is rapidly 
cleared from the circulation leaving behind very few HDL particles to 
contribute in reverse cholesterol transport from the vasculature. Ultimately 
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resulting in increased plasma triglyceride and LDL levels and decreased 
plasma HDL level.  
Insulin is the major physiological regulator of adipose tissue lipolytic 
activity by inhibiting lipolysis. Lipolysis of adipose tissue triglycerides is the 
main source of plasma FFA. In the case of insulin resistance, the rate of 
lipolysis is increased producing more amount of fatty acids which in turn 
further inhibit the antilipolytic action of insulin thereby producing additional 
lipolysis.  
In skeletal muscle, the mechanism responsible for free fatty acids-
induced insulin resistance is alteration in intracellular insulin signalling and 
impaired insulin-mediated glucose uptake. An acute increase in plasma free 
fatty acids concentrations from approximately 400 μM (normal basal 
concentration) to approximately 800 μM (concentration during short-term 
fasting) causes a marked increase in intramyocellular fatty acid metabolites 
which include long-chain fatty acyl-CoA and diacylglycerol. These 
metabolites are potent allosteric activators of protein kinase C which 
phosphorylates serine/threonine sites of insulin receptor substrate-1. This 
results in inhibition of insulin‟s ability to activate phosphoinositide 3-kinase 
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activity and decreases downstream events including translocation of GLUT- 
4 from the cytoplasm to the surface of the cell needed for glucose transport. 
Defective skeletal muscle mitochondrial function has been identified 
in persons who have insulin resistance and are at increased risk for 
developing Type 2 Diabetes Mellitus. Impaired mitochondrial fatty acid 
oxidation increases the intracellular accumulation of fatty acids leading to 
impaired insulin action.  
Development of atherosclerotic  plaque: 
 Fatty streak is the earliest lesion of atherosclerosis made up of lipid 
laden foam cells, derived mainly from circulating monocytes and few 
smooth muscle cells. Foam cells represent circulating monocytes, that 
penetrate between endothelial cells, entered the intima and taken up 
lipoproteins and consequent storage of cholesterol esters in multiple 
droplets.
 
In diabetes, hyperglycemia and hypercholesterolemia activates and 
induces expression of specific adhesion molecules like VCAM, ICAM, E-
SELECTIN etc on the endothelial cells.   
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It also influences the behaviour of circulating monocytes increasing 
its adhesion to the endothelium. Monocytes adhere and penetrate in response 
to chemotactic factors, like MCP-1 which is unregulated in Diabetes. The 
extracellular lipid begins to accumulate in the intima which often associates 
with proteoglycans of  extracellular matrix. Sequestration within the intima 
separates lipoproteins from plasma antioxidants and favours oxidative 
alteration.           
Evolution of fibro fatty streak  
The next step is accumulation of lipids. Hyperglycemia in Diabetes 
Mellitus causes glycation of LDL. Glycation of LDL apoB occurs mainly in 
lysine residues in the LDL receptor binding domain, essential for specific 
recognition of LDL by the LDL receptors. Thus it leads to impairment of 
LDL receptor mediated uptake which inturn leads to decreased clearance of 
LDL. 
Glycation confers increased susceptibility of LDL to oxidative 
modification. Advanced glycation of an amine containing phospholipid 
component of  LDL is accompanied by progressive oxidative modification 
of unsaturated fatty acid residues. LDL glycation enhances its uptake by 
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aortic intimal cells and monocyte derived macrophages stimulating the 
development of foam cells.
 
 Glycation and oxidation are closely related and mutually accelerate 
each other. Product of combined glycation and oxidation of LDL 
(glyoxidation) is more atherogenic than glycated or oxidized LDL alone. 
 
 Dyslipidemia in Diabetes Mellitus ( ↓ HDL &↑ TGL) reduces reverse 
cholesterol transport and increases the formation of small dense LDL, which 
is more prone for oxidation. Small dense LDL enters the arterial intima more 
easily and binds more readily to the proteoglycans, through specific 
sequence of apoB, than the larger fraction. Binding of LDL in the arterial 
intima  increases the dwelling time and provides opportunity for oxidation of 
LDL lipids.
 
Oxidised LDL has several  pro atherogenic properties including the 
rapid uptake by macropages to form  foam cells, chemoattraction for 
circulating monocytes, promotion of the differentiation of circulating 
monocytes into tissue macrophages and inhibition of the mobility of resident 
macrophages. It is also cytotoxic to several types of cells and immunogenic. 
          Macrophage foam cells, leucocytes and resident vascular wall cells 
can secrete inflammatory cytokines and growth factors (TNFα,IL-1,MCP-
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1,PDGF,FGF,TGF,etc) that amplify leucocyte recruitment and causes 
smooth muscle cell migration and proliferation.  Thus conversion of fatty 
streak to fibrous plaque occurs by accumulating vascular smooth muscle 
cells and accumulating a complex extracellular matrix that consists of 
proteoglycans, collagen and elastin. 
Fibrous cap formation: 
           The fibrous material that separates the plaque core from the luminal 
surface of the vessel is termed as fibrous cap. The fibrous cap provides a 
barrier to thrombosis by separating the pool of tissue factor from the  
FactorVII in the blood. Increased matrix metalloproteinase activity and 
macrophage in Diabetes Mellitus may shift the proteolytic balance within 
the cap leading to degradation of extracellular matrix and weakening of its 
structural integrity, thus increasing susceptibility to rupture or erosion. 
Atherothrombosis: 
Disruption of plaque surface allows the tissue factor to bind 
circulating factorVII in blood resulting in the generation of active factorVIIa 
and formation of tissue factor-factorVIIa complex, leading to activation of 
coagulation cascade. Elevated levels of tissue factor in vascular tissue, 
predispose the activation of coagulation cascade and increased arterial 
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expression of  Plasminogen activator inhibitor -1 in diabetes may impair the 
dissolution of nascent thrombi and this may lead to occlusive thrombi and 
thereby can cause acute coronary syndrome. Thus oxidation of LDL plays 
major role in development of atherosclerosis in Diabetes Mellitus. 
3.CENTRAL OBESITY 
According to the new criteria of IDF, Metabolic syndrome can also be 
called as central obesity syndrome Gary 2006. Central obesity is a high risk 
factor for cardiovascular disease. Central obesity is more metabolically 
active than peripheral fat. Recently, studies have proposed that central 
adiposity precedes the development of the other components of metabolic 
syndrome and weight reduction at that point could be the best way to prevent 
it. Pladevall et al., 2006, Steele et al., 2008 recommends that waist 
circumference to be measured regularly to assess individuals for increased 
risk for insulin resistance and to target individuals for health promotion 
interventions. Though insulin resistance is the major factor for the 
development of metabolic syndrome, it is the obesity that provides the 
connection between the insulin-resistant, dyslipidemic and hypertensive 
factors Wingard et al.,1996. 
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Body fat distribution are of two types  
1. 90 % of the fat is Subcutaneous fat. 
2. Remaining 10 % of fat is Visceral fat. 
Subcutaneous fat is the kind felt when the skin is pinched. It can be 
measured using body fat calipers, which gives a rough estimate of total body 
adiposity. 
Visceral fat lies beneath the abdominal muscles and can only be detected 
by MRI. Since, MRI scans are not a cheap procedure it is not recommended 
as a diagnosis tool for diabetes risk. Research has shown that the size of our 
belly is a relatively reliable indicator of the health risks linked to visceral fat, 
which can be assessed by waistline measurement. Since around 10% of our 
total fat is likely to be stored as visceral fat, therefore if a person carries 
higher amounts of body fat than the recommended level, the person  is likely 
to have more visceral fat than is healthy.  
Visceral fat is more dangerous than the subcutaneous fat. It is found 
that stress has a significant effect on where fat is stored in our body. 
Researchers have shown that cortisol, the stress hormone, significantly rises 
the storage of visceral fat. 
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Visceral fat releases free fatty acids directly into portal circulation,  
carrying blood directly to the liver. It also gets accumulated in the pancreas, 
heart and other organs. This leads to organ dysfunction, impaired insulin 
regulation, blood glucose and cholesterol level as well as abnormal heart 
functions. This is known as lipotoxicity (Havard College 2006). 
 Adipose tissue produces several inflammatory cytokines 
(adipokines), which induces insulin resistance, and adiponectin which can 
rise the insulin sensitivity Kershaw and Flier, 2004. The adipokines include 
tumour necrosis factor α (TNFα) and interleukin-6 (IL-6), which are 
proinflammatory and induce insulin resistance and vascular dysfunction. By 
contrast, adiponectin is a protective adipokine that increases insulin 
sensitivity in the liver, reduces hepatic glucose production and increases 
skeletal muscle glucose and fatty acid oxidation. Adiponectin levels are 
reduced in obesity, Type 2 Diabetes Mellitus and metabolic syndrome. 
4.HYPERTENSION 
One of the symptoms of metabolic syndrome is hypertension. It is a 
silent symptom which may remain undetected for long period. It is an 
important risk factor for development of cardiovascular disease. The relation 
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between insulin resistance and hypertension is well established. Several 
different mechanisms are proposed. 
Insulin is a vasodilator when given intravenously with secondary 
effects on sodium reabsorption in the kidney. In case of insulin resistance, 
the vasodilatory effect of insulin is lost but the sodium reabsorption by the 
kidneys is preserved.  
Fatty acids themselves can cause relative vasoconstriction. 
Hyperinsulinaemia leads to increased sympathetic nervous system 
(SNS) activity, resulting in the development of hypertension. 
Hypertension is a chronic condition of concern, due to its role in the 
causation of cardiovascular mortality which accounts for 20-50 % of all 
deaths. Hypertension  is  one of the common  disease, leading  to many life  
threatening complications including, renal failure, cerebrovascular        
accidents   and   atherosclerotic  coronary artery disease. But, the effects of  
hypertension are not diagnosed in its  early stages. About 85% of  
individuals  affected  with metabolic syndrome will  have elevated  blood 
pressure.    
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Criteria  for diagnosis of Hypertension 
Systolic BP mmHg Diastolic BP mmHg Category 
 Less  than  120    and Less than  80  Normal 
120 – 139            or 80 – 89 Prehypertension 
140 – 159            or 90 – 99 Stage 1 Hypertension. 
≥ 160                 or ≥ 100 Stage 2 Hypertension. 
Hypertension is divided into primary (essential) and secondary.   
Among all the cases of hypertension, 90% belongs to primary     
hypertension. Secondary hypertension is due to congenital narrowing of 
aorta, tumors of adrenal glands, diseases of kidney, etc. Altogether   these    
diseases were estimated to account for 10% of cases of   hypertension. 
5.PROINFLAMMATORY STATE  
Yudkin et al., 1999 noted that low-grade inflammation is associated 
with insulin resistance. The origin of the inflammatory state and endothelial 
dysfunction are adipocyte-generated inflammatory cytokines, which 
correlate strongly with insulin resistance. Circulating signal molecules from 
fat include FFAs, adiponectin, IL-6, resistin, leptin and TNF-α. Studies 
shows associations of levels of C-reactive protein and interleukin-6 with 
measures of obesity and of chronic infection as their presumed determinants. 
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Studies  also related levels of C-reactive protein and interleukin-6 to markers 
of the insulin resistance syndrome and of endothelial dysfunction. Metabolic 
syndrome and obesity are a kind of stress that leads to activation of 
inflammatory pathways. In fact the inflammation is low grade chronic 
inflammation. Researchers have named this inflammatory state as 
―metainflammation, which means metabolically triggered inflammation.  
6.PROTHROMBOTIC STATE  
Increased levels of plasma plasminogen activator inhibitor (PAI)-1 
and fibrinogen are also associated with the metabolic syndrome. Thus, 
prothrombotic and proinflammatory states are interconnected. 
The study of plasminogen activator inhibitor-1 helps in better 
understanding of association between hemostatic markers and metabolic 
syndrome. A study was conducted by Aso et al., 2005 to determine whether 
plasma concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI) 
in patients with Type 2 Diabetes Mellitus were associated with components 
of metabolic syndrome, including high-sensitivity C-reactive protein (hs-
CRP), plasminogen activator inhibitor (PAI)-1 and LDL cholesterol. The 
result indicated positive correlation between LDL cholesterol and plasma 
TAFI with Type 2 Diabetes Mellitus. Co-existence of metabolic syndrome 
and hypercholesterolemia accelerates inflammation and elevated TAFI and 
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PAI-1, inhibits fibrinolysis. PAI-1 is an important risk factor for metabolic 
syndrome. Three other biomarkers, CRP, IL6 and fibrinogen are also 
associated with the metabolic syndrome cluster. These 4 biomarkers 
contribute in the metabolic syndrome risk assessment Kraja AT et al., 
2007.  
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RISK FACTORS 
 The metabolic syndrome also has multiple risk factors such as obesity, 
physical inactivity, unhealthy diet, ageing, disruption of sleep, smoking and 
stress. 
1. OBESITY 
Central adiposity is a key feature of the metabolic syndrome, which 
implies that the syndrome's prevalence is driven by the strong relationship 
between waist circumference and increasing adiposity. Even then the 
patients of normal weight can also be insulin resistant. Those are called 
metabolically obese, normal-weight individuals. These persons have 
increased amount of visceral adipose tissue. Effective weight reduction is 
known to improve individual components of the metabolic syndrome, while 
weight gain during adulthood is known to exacerbate individual components 
of the metabolic syndrome. 
 Obesity is a chronic condition characterized by the presence of 
abnormal or excessive body fat. Obesity also increases the chance of various 
chronic diseases like cardiovascular disease, stroke, Type 2Diabetes Mellitus 
and few types of cancer Haslam D 2005. At an individual level, excessive 
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body fat results when energy intake exceeds energy expenditure Lau D et 
al., 2007. 
The odds of having metabolic syndrome increase with increasing 
levels of BMI in men and women. The metabolic syndrome was found in 
4.6%, 22.4%, and 59.6% of normal weight, overweight and obese men 
respectively and in 6.2%, 28.1% and 50.0% of normal weight, overweight 
and obese women respectively based on the NHANES III. Thus most 
persons with the metabolic syndrome are overweight or obese, suggesting 
that obesity in conjunction with genetic aspects of susceptibility may link the 
components of the metabolic syndrome.  
Sedentary occupations with high levels of sitting time and lower 
demand for physical activity have been associated with weight gain and 
obesity.  
Assessment of Obesity 
Obesity is usually easily identified at first sight. It is diagnosed by    
physical appearance which is referred to as “eyeball test”. 
In clinical  medicine, currently  waist circumference, waist hip ratio 
and BMI  are  the  commonly  used  parameters  for assessing  obesity. The 
introduction of measuring fat cells has opened up a new field in obesity 
research. 
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Body Mass Index  (BMI) 
BMI is the most often used method for estimating obesity. When BMI  
is  more than  30,  the individual is  considered  to be  obese.  
BMI  is calculated  by  using  the Quetelet‟s Index. 
            BMI =   Weight  (Kg)/ Height  (m
2
). 
For adults, overweight and obesity are defined as a BMI of 25 kg/m
2
 
to 29.9 kg/m
2
 and 30 kg/m
2
or higher, respectively. 
Waist Circumference   and   Waist-to-Hip Ratio (WHR)  
 
The mid point between iliac crest and the lowest rib was measured    
with an inch tape in  standing posture for assessing the waist circumference. 
In the gluteal region the widest part was measured as Hip circumference  and 
Waist Hip Ratio was calculated. 
The distribution of fat is better assessed  by Waist Hip Ratio. The risk 
factors for chronic diseases like coronary artery disease is associated with an 
increase in waist  circumference. The total body fat and intra-abdominal fat 
mass is better assessed by waist circumference which is an easy and 
convenient  measure. It is not related to height, but is better correlated with 
change  in Waist  Hip Ratio and  Body Mass Index.  
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There are two types of  body shape that are related to the  health –  
 Apple shaped body 
 Pear shaped body 
Body shape can be determined by using the Waist Hip Ratio. It is 
important because it indicates the fat distribution in your body. The body 
shape is determined by a number of factors. These include genes, diet and 
life style. 
People with apple-shaped bodies carry more weight around their 
abdomen that is, they have more amount of visceral fat, hence this can be 
associated with a greater risk of heart disease, diabetes and stroke. 
Those with pear-shaped body have a narrower waist and carry more 
weight around their hips and thigh, it indicates a lower metabolic risk. 
     A Waist Hip Ratio of 0.8 or above indicates an apple shaped body. A 
ratio of below 0.8 indicates a pear shaped body. 
      The prevalence of obesity among adults in the  year 2000 was    
found to  be  55%   out  of  which  24% were females and 21%  were  males. 
Throughout  the world,  there   are  about  250 million  obese  individuals.  
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In United States alone, 30,000 deaths were related to over weight and    
obesity.  
  In a study conducted at Mangalore, around  29.7% of people were 
affected with metabolic syndrome and the prevalence was more in female 
subjects which is attributed  by their increased waist circumference.  
2. SEDENTARY LIFESTYLE 
Physical inactivity is a predictor of cardiovascular disease and related 
mortality rate. Many components of the metabolic syndrome are associated 
with a sedentary lifestyle including increased adipose tissue (mainly 
visceral), decreased HDL cholesterol and increased triglycerides, blood 
pressure and blood glucose in the genetically susceptible individuals. 
Individuals who watched television or videos or used the computer >4 hours 
daily have a twofold increased risk of the metabolic syndrome than those 
who carried out those behaviors for <1 hour daily. Regular and sustained 
physical activity positively influences individual components of the 
metabolic syndrome. 
Physical activity has been defined as any bodily movement produced 
by skeletal muscles that result in energy expenditure beyond resting 
expenditure Thompson P et al., 2003. Many previous studies have 
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demonstrated that physical activity is associated with reduced risk of the 
metabolic syndrome and physical inactivity may be an important modifiable 
risk factor in the etiology of the metabolic syndrome Torjesen P et al., 
1997. While the metabolic syndrome has increased in the past few decades, 
the amount of physical activity and energy expenditure has declined during 
this time. Thus, individuals with a lack of physical activity may be at risk of 
metabolic syndrome.  
Ekelund and colleagues studied the prospective associations between 
energy expenditure due to physical activity and the progression toward the 
metabolic syndrome in 605 middle aged men and women who do not suffer 
from metabolic syndrome over a 5.6 year follow-up period. The measure of 
physical activity in this study was based on the amount of energy 
expenditure above resting level including all types of activity performed in 
the routine life. The study predicted the progression towards metabolic 
syndrome independent of other potential confounding factors (standardized 
β = -0.00085, P = 0.046).  
3. DIET  
 Insulin sensitivity is influenced not only by total energy intake but 
also by diet composition.  
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Intake of high monounsaturated fat diet greatly improves the insulin 
sensitivity when compared to a high-saturated-fat diet. But this beneficial 
effect is not seen in individuals whose total fat intake exceeds 38% of total 
energy Vessby et al., 2000. 
Since dietary carbohydrate is a major precursor of blood glucose, 
increasing the amount of carbohydrate in the diet will raise blood glucose 
levels mainly in the postprandial period. Blood glucose concentration 
represents an important prompting factor for insulin release, hence a high 
carbohydrate diet will also lead to increased insulin levels. Whether the 
effects of a high-carbohydrate diet is more pronounced on glucose or insulin 
levels, depends on the insulin secretory capacity of the endocrine pancreas 
Reaven, 1997. 
Glucose and lipid metabolism are strongly related and any imbalance 
of carbohydrate metabolism by a high-carbohydrate diet will also increase 
plasma triglycerides and decrease plasma HDL concentrations. Fibrinolysis 
is also deteriorated by a high-carbohydrate diet.  This type of diet is also 
associated with an increase of PAI1 in blood Lopez-Segura 1996. 
Other food constituents that affects the metabolic abnormalities and 
cardiovascular  disease risk factors clustering in the metabolic syndrome are 
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 an excessive intake of alcohol (more than 30 gm/day) can raise both 
plasma triglyceride and blood pressure levels Kiechl et al.,1996. 
 A high intake of sodium chloride can also increase the blood pressure. 
4. AGEING 
Ageing is defined as a sequence of morphological and functional 
changes which take place eventually. It also refers to the worsening of the 
biological functions after an individual has attained the maximum 
reproductive potential. 
Many older individuals has increased abdominal fat despite a normal 
BMI, a factor that can decrease the utility of BMI as a predictor of Type 2 
Diabetes Mellitus in older individuals. Ageing is also coupled with a raise in 
proinflammatory cytokines, which are known to hinder the insulin action. 
These cytokines are a resultant from both the age-associated accrual of 
visceral fat and secretion of proinflammatory cytokines by increasing 
number of senescent cells. Collectively these age-related alterations in 
metabolism and body fat distribution are active participants in a vicious 
cycle that can accelerate the ageing process and the onset of disease. 
Another metabolic regulator derived from adipose tissue and linked to 
aging is the hormone adiponectin. Contrast to other fat-derived cytokines 
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that oppose insulin action, it is an insulin sensitizer with anti-inflammatory 
properties and a potent activator of AMP-activated protein kinase (AMPK). 
Adiponectin is paradoxically increased in lean individuals or in response to 
caloric restriction.  
Ageing is associated with progressive loss in mitochondrial function 
in various tissues including skeletal muscle. Mitochondria are the major 
source of reactive oxygen species generation which causes oxidative damage 
to the macromolecules such as nuclear and mitochondrial DNA. This has led 
many to embrace the mitochondrial theory of ageing which states that 
mitochondrial dysfunction is a fundamental cause of cellular ageing and 
senescence.  
The impaired mitochondrial function may impinge on insulin 
signalling is thought to involve reduced or incomplete β-oxidation of fatty 
acid substrates in metabolically active tissues such as liver and skeletal 
muscle. Investigations have reported an association between insulin 
resistance and impaired glucose tolerance with decreased mitochondrial 
oxidative activity and ATP synthesis in elderly and Type 2 Diabetic 
individuals. A study comparing mitochondrial function between healthy, 
lean, elderly individuals and matched lean, healthy young subjects found a 
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40% reduction in mitochondrial activity and oxidative phosphorylation in 
the elderly subjects with insulin resistance. Similarly, young insulin-resistant 
offspring of diabetic parents had reduced mitochondrial activity and 
increased fat content in skeletal muscle compared with insulin-sensitive 
control subjects. 
The metabolic syndrome affects 44% of the U.S. population older 
than age 50 years. The age dependency of the syndrome's prevalence is seen 
in most populations around the world. 
5. STRESS  
 Stress is defined as a state in which harmony or homeostasis is 
actually threatened or perceived to be so evoked by various cognitive (e.g., 
anxiety, fear, depression) and/or somatic stressors (e.g., pain, lipid 
accumulation, inflammation) when the hazard to homeostasis exceeds the 
threshold. 
 Psychosocial stress also plays a role in the pathogenesis of the 
metabolic syndrome. Continuous exposure to work-related stress can alter 
autonomic nervous system and neuroendocrine systems that control the 
reactions to stress. The neuroendocrine responses from the hypothalamic-
pituitary-adrenal (HPA) axis and the sympathetic nervous system stimulate 
stress-related cortisol secretion. This contributes to the development of 
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chronic diseases such as dyslipidemia, abdominal obesity, hypertension and 
insulin resistance. 
There are reports indicating that despite regular exercise and a proper 
diet, subjects under prolonged stress developed metabolic alterations 
including distinctive central obesity, biochemical changes and a slight 
hypertension towards the metabolic syndrome Branth S et al., 2007.There is 
a dose-response relation between exposure to work stressors and risk of the 
metabolic syndrome independent of other relevant risk factors Chandola T 
et al., 2006. 
Although mechanisms behind this relationship remain unclear, 
prolonged exposure to work stress may affect the autonomic nervous system 
and neuroendocrine responses that can contribute to the development of the 
metabolic syndrome. Neuroendocrine responses to stress activate the HPA 
axis which results in the secretion of steroid hormones including 
corticosteroids and catecholamines which are major stress hormones. 
Cortisol is a corticosteroid hormone which is secreted from the adrenal 
cortex under the control of the HPA axis. During short-term acute stress, 
plasma cortisol levels are increased by the activation of the HPA axis for 
survival through homeostatic adjustments. However, frequent chronic stress 
may sustain elevated cortisol secretion that may damage to the HPA axis 
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with time resulting in a maladaptive process. Stress-related cortisol secretion 
has been linked with individual components of the metabolic syndrome.  
Hence, chronic stress at work is a major risk factor for the metabolic 
syndrome. 
6. SMOKING 
Smoking is widely accepted as a major risk factor for cardiovascular 
disease Frati AC et al., 1996. Previous studies have shown that smoking 
reduces insulin sensitivity, induces insulin resistance and enhances 
cardiovascular risk factors, such as elevated plasma triglycerides, decreased 
HDL–cholesterol and hyperglycemia. 
In Kawada‟s 1-year follow-up study, current smokers had a higher 
risk of metabolic syndrome than nonsmokers, independent of age, body 
mass index, insulin resistance and other lifestyle factors. In contrast, ex-
smokers did not have a significantly greater risk of metabolic syndrome than 
nonsmokers. The most effective way for smokers to reduce their risk of 
metabolic syndrome and cardiovascular disease is to stop smoking. 
However, Nakanishi et al., 2005highlighted that smoking cessation is 
also associated with a 1.3-fold risk of metabolic syndrome as a result of 
subsequent body weight gain. 
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 Mizuno et al., 2005 reported that waist circumference is significantly 
higher in obese subjects who smoke compared to the nonsmokers. Smoking 
seems to hasten the visceral fat accumulation and promote obesity-related 
disorders. Waist circumference is strongly associated with visceral fat mass 
which is influenced by the plasma cortisol concentration. Smokers have 
higher fasting plasma cortisol concentrations than nonsmokers. Higher 
cortisol concentrations may be a consequence of the stimulation of 
sympathetic nervous system activity which is induced by smoking 
Williamson DF et al., 1991. 
Sex hormones may also get involved Haarbo J et al., 1991. In men, 
visceral fat increases when testosterone concentrations decrease and the 
administration of testosterone to middle-aged men reduces their visceral 
adipose tissue by increasing lipolysis. Smoking may reduce testosterone 
concentrations in men. Overall, these results suggest that in addition to 
excess cortisol and a reduction of testosterone in men may be involved in the 
effect of smoking on visceral adipose tissue hence leading to insulin 
resistance and development of metabolic syndrome. 
7. DISRUPTED CHRONOBIOLOGY/SLEEP 
 Circadian rhythms are such an innate part of our lives. Recently, some 
studies have suggested that the disruption of the circadian system may be 
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causal for the manifestations of metabolic syndrome. Shift work, sleep 
deprivation and bright light exposure at night are related to increased 
adiposity and prevalence of metabolic syndrome. Surprisingly, circadian 
system impairment is not only the result of obligatory shift work schedules 
but is also an emerging issue in adolescent and young adults because their 
leisure activities result in voluntary sleep curtailment.  
Epidemiological studies show that shift work is associated with 
obesity, hypertriglyceridemia, low HDL, abdominal obesity, diabetes and 
cardiovascular diseases.  
Postprandial response are observed in shift workers with chrono- 
disruption of the melatonin profile. One of the most interesting recent 
findings is that shift work is an independent risk factor in the development of 
metabolic syndrome.  
A study performed in day workers and shift workers indicated that 
shift workers had higher BMI even though the diet quality was even better in 
shift workers and the level of physical activity was similar between day and 
shift workers. 
Interesting results come from the studies relating sleep duration and 
metabolic risk. The amount of sleep has declined by 1.5 hours over the past 
century with an important increase in obesity. Moreover, one-third of adults 
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sleep, less than 6 hours during night. Clinical studies show that healthy 
individuals restricted to 4 hours of sleep for six consecutive nights exhibit 
impaired glucose tolerance and reduced insulin responsiveness following a 
glucose challenge.  
8. EXCESSIVE ALCOHOL CONSUMPTION 
 Protective and detrimental associations have been reported between 
alcohol consumption and the metabolic syndrome from the National Center 
for Chronic Disease Prevention and Health Promotion. This may be due to 
variations in drinking patterns and different alcohol effects on the metabolic 
syndrome components.  
US Dietary Guidelines recommendations of not more than 1 drink per 
day for women or 2 drinks per day for men. Risk for the metabolic syndrome 
was increased by daily consumption that exceeded US Dietary Guidelines 
recommendations (odds ratio [OR], 1.60; 95% confidence interval [CI], 1.22 
- 2.11) and by binge drinking once or more per week (OR, 1.51; 95% CI, 
1.01 - 2.29). Drinking in excess of the Dietary Guidelines was associated 
with an increased risk for individual components of the metabolic syndrome. 
The mechanisms underlying the relation of alcohol drinking with the 
metabolic syndrome may be explained by the relation with its components. 
Studies have reported that alcohol consumption is positively associated with 
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abdominal obesity. A meta-analysis of human experimental studies 
suggested that moderate alcohol drinking is positively associated with both 
HDL-cholesterol and triacylglycerol concentrations and the association did 
not differ significantly across beverage types. Consistent evidence on blood 
pressure elevated by heavy drinking has been reported while outcomes 
regarding light or moderate drinking have shown varied effects on blood 
pressure, such as beneficial, injurious, or similar effects compared with  
abstaining from alcohol. Observational studies have found an inverse 
association between alcohol consumption and glycemic control, atleast in 
part through enhanced insulin sensitivity. However, heavy liquor drinking 
was shown to increase the risk of Type 2 Diabetes Mellitus. 
On the basis of these reports, it can be postulated that heavy drinking, 
in particular liquor drinking, has a detrimental influence on waist 
circumference, triacylglycerols, blood pressure and glucose leading to an 
increase in metabolic syndrome risk.  
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OCCUPATIONAL DRIVERS 
Epidemiological studies have been done extensively to determine the 
prevalence and associated risk factors of the metabolic syndrome in the 
general population, yet less attention has been paid to its prevalence and risk 
factors for specific occupational groups such as in occupational drivers. 
The reasons for excess risk of metabolic syndrome in occupational 
drivers are, 
Lots of work and little pay  
 Drivers are expected to drive up to fourteen hours per day, receiving 
roughly ten hours off prior to the beginning of the next shift. Even though 
law regulating the amount of driving over the course of a day and week 
exist, these rules are usually bent and broken. 
Drivers rarely receive more than one day of work off a week. The 
chance of death on the job is extremely high. 
The work shift is also a risk factor for chronic diseases, like 
cardiovascular disease and metabolic disorders, because of altered circadian 
rhythm, lifestyle change and stress at work Frost P et al., 2009. 
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Unhealthy food habits 
 In addition to long hours, drivers rarely eat healthy food preparation. 
They often take high calorie diet. High carbohydrate meal consumption is 
related to hyperinsulinaemia, hyperglycaemia and hypertriglycemia that are 
well known to predict an increase of body fat in working individuals .The 
hours spent in sitting along with poor food choices make them obese. 
Inaccessibility of Health care 
 The hours worked by drivers make it nearly impossible to make or 
keep medical appointments. This confines their options when a health 
problem arises leading many drivers to ignore symptoms. 
Lack of regular exercise 
 Most drivers are poorly educated and they are not aware of the 
importance of doing regular exercises. They hardly find time to do regular 
exercise which in turn increases the chance of obesity. 
Smoking & alcohol intake 
 In order to overcome the stress in their work place, drivers are prone 
to develop the habit of smoking and alcohol intake.   
49 
 
Road transport drivers are one of the professional groups whose 
activities have a strong impact on public safety. Moreover, study by      
Evans L on 1996 states that behavioural factors among professional drivers 
contribute considerably to the occurrence of traffic accidents. 
Hence it is essential to initiate early detection of metabolic syndrome 
in this high risk population groups so that preventive measures can minimize 
the consequences. The aim of this study was to estimate the occurrence of 
metabolic syndrome among occupational drivers and studying the 
contributors of metabolic syndrome among them. 
Evaluating the prevalence of the metabolic syndrome over time and 
identifying possible risk factors is critical to reduce the risk of 
cardiovascular  disease and further reduce the premature death among this 
occupational cohort. 
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COMPLICATIONS  
1. Cardiovascular Disease 
The relative risk for cardiovascular disease in patients with the 
metabolic syndrome in the absence of diabetes is between 1.5-fold and 3-
fold.  
The pathophysiological mechanism by which the metabolic syndrome 
increases cardiovascular risk remains under debate. Earlier definitions by the 
World Health Organization and the European Group for the Study of Insulin 
Resistance emphasize the independent role of insulin resistance as the 
underlying component of the metabolic syndrome. Insulin resistance 
progresses toward hyperinsulinemia and hyperglycemia thus triggering 
peripheral vasoconstriction and sodium retention. Hepatic production of  
very low-density lipoprotein also increases, leading to hypertriglyceridemia, 
low HDL cholesterol, elevated apolipoprotein B, elevated small LDL 
cholesterol and consequently atherosclerosis. As a result of these lipid 
imbalances, individuals with the metabolic syndrome typically exhibit a 
prothrombotic and proinflammatory state.  
More recent definitions by the NCEP, rNCEP and the International 
Diabetes Federation emphasize central obesity as the underlying component. 
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Adipocytes secrete mediators including TNF-α, leptin, adiponectin and 
resistin which lead to insulin resistance. In these definitions, it is postulated 
that central obesity causes systemic hypertension and dyslipidemia 
independently and through the induction of insulin resistance. 
Regardless of which definition is used, insulin resistance and central 
obesity are postulated to be the key components of the metabolic syndrome 
and both lead to glucose intolerance and dysglycemia.  
Cardiovascular disease is still most frequent cause of death among  
men under  65 years. In many developed countries  it poses the largest public 
health  problem. The etiology  of cardiovascular disease   is multifactorial . 
Risk  factors for  Cardiovascular disease: 
Modifiable Non modifiable 
Obesity 
Diabetes 
Hypertension 
Cigarette smoking 
Elevated serum cholesterol 
Stress 
Sedentary habits 
Age 
Sex 
Genetic causes 
Family history 
Personality 
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         Any individual can be categorized under the high risk group for   
developing  atherosclerotic cardiovascular disorder, if any one of the  above    
mentioned  risk  factor  is present.  80% of deaths in patients with Type 2 
Diabetes Mellitus were attributed  by  non-ischemic cardiovascular disease, 
stroke and myocardial infarction. 
Independent of other risk factors, Type 2 Diabetes Mellitus not only 
increases the risk of cardiovascular  morbidity and mortality,  but also offers 
a synergistic interaction with other    causative  factors such as hypertension  
and dyslipidaemia.  
Women are more vulnerable to the cardiovascular effects of Type 2 
Diabetes Mellitus because they appear to lose the protective effects of 
estrogen in the premenopausal period Willeit J et al., 1997. 
            Rajeev Gupta et al., 2012 from Jaipur, conducted  a study during 
the year 2002 to 2006 and stated  that,  the  risk  factors  for developing     
cardiovascular disease  in the urban population is always high.
 
Murthy et al., 2012 from Guntur district in Andhra Pradesh, high 
lightened that there is positive correlation between  impaired  glucose  
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tolerance and high levels  of  triglycerides  and low density lipoprotein 
levels, which is linked with  escalating  prevalence  of cardiovascular  
disease.
 
In  a survey conducted at Tenali town,  in   Andhra Pradesh, between 
July 2009 and October 2009, the overall prevalence of  cardiovascular  
disease was  5.4%. The prevalence rate of  cardiovascular disease was11.3% 
in persons with  diabetes, 23.5 % in those with  impaired glucose tolerance 
and 3%  in  persons  with   normoglycemia Dakshina  Murthy et al., 2012.
 
In a Finnish population diabetes augmented the risk of myocardial 
infarction fivefold and  increased the risk of death from heart disease. 
2. Type 2 Diabetes Mellitus 
Overall, the risk for Type 2Diabetes Mellitus in patients with the 
metabolic syndrome is increased by 3- 5 fold. In addition to predicting 
cardiovascular disease  morbidity and mortality, the metabolic syndrome is 
strongly associated with the development of Type 2 Diabetes Mellitus itself 
an important risk factor for cardiovascular disease . However, even before 
levels of blood glucose are high enough for a person to be diagnosed with 
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diabetes, raised blood glucose level and related changes in blood lipids 
(increase in triglycerides and decrease in the „good‟ cholesterol HDL-c) 
increase a person‟s risk of cardiovascular disease. 
Diabetes Mellitus is a multisystem  disorder  caused  by  the  complex 
interaction of genetic  and  environmental factors. Diabetes is a metabolic 
disorder characterized by chronic hyperglycemia, resulting in various 
clinical manifestations. It is a chronic  disease resulting  in  many dreaded 
complications like  ocular, neurological,  renal, cardiovascular  and  other 
intercurrent infections.
 
            In the recent  years,  the  age  of  onset of  diabetes among Indians      
has been shifted to much younger age group. This will have a great  impact 
in nation‟s economy and health. The prevalence of  diabetes is more  in 
urban population because of the epidemiological transition with decreased 
physical  activity and  unhealthy  dietary  patterns. When compared  to other  
ethnic  groups, there is  high prevalence   of  stroke   and  cardiovascular 
disease among the Asian Indians. The incidence of micro vascular 
complications like diabetic retinopathy  and  neuropathy is low. 
One of the main cause for increased incidence of premature     
cardiovascular disease  and  diabetes among  Indians  is  due  to genetic 
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 factors and also the “Asian Indian Phenotype”. It includes central  adiposity  
with increased waist circumference,  insulin  resistance, raised C-reactive 
protein levels, lower adiponectin and lower  BMI. For  prevention  and 
postponement of onset  of Diabetes Mellitus, early  intervention through 
proper lifestyle modification  and  timely  screening  of  individuals at risk 
should be carried out. It  will  result in  great economic  improvement of  our 
country and  reduces the burden of  our  society. 
Clinical  classification of  Diabetes Mellitus: 
1.Gestational Diabetes mellitus (GDM) 
2. Impaired glucose tolerance (IGT) 
3.Diabetes  Mellitus  (DM). 
i) Type 1 DM  --  IDDM -- Insulin  dependent Diabetes Mellitus. 
ii)Type 2 DM -- NIDDM--Non Insulin dependent Diabetes Mellitus. 
iii) Secondary Diabetes --drug induced, genetic, hormonal, pancreatic   
and other abnormalities 
iv)Malnutrition --related Diabetes Mellitus.  
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NIDDM is much more common than IDDM. The risk factors which     
determine the occurrence of Type 2 Diabetes Mellitus includes ethnicity,    
age  and  sex. The presence of other chronic disorders makes the condition   
more  worse. 
         Currently the young adults and adolescents are in the high risk     
category  for  developing diabetes. Previously it  was believed  that Type  2 
Diabetes Mellitus was  a  disease of  elderly  and middle  aged  people which 
has recently escalated in all age groups and is now seen also in younger age 
groups. 
          In children and young  adults, there  is an alarming increase  in the 
prevalence of Type  2  Diabetes Mellitus. The National Health and Nutrition 
Examination Study (NHANES) data for 1999 to 2000 suggest that10.4% of 
2-to 5-year olds, 15.3% of  6 to11 year olds,15.5% of 12 to 19 year olds 
have a BMI above 95
th  
percentile adjusted for sex and age. It represents an 
approximately 30% increase over the previously determined data for 1988 to 
1994. Impaired glucose tolerance and Type  2 Diabetes Mellitus have now 
emerged as critical health  issue in overweight children and young adults 
Harris  M I et al., 1998. 
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The diagnosis of diabetes rests on the measurement of plasma glucose 
levels. The  diagnostic criteria for diabetes were changed in 1997. The most 
significant changes were the level of fasting glucose that is recognized as 
diagnostic  for diabetes  which  was decreased  from140  to  126mg/dl and 
the introduction of  a category of  impaired fasting glucose.   
  Levels of hemoglobinA1c are not currently recommended for    
diagnosing  diabetes. The major reasons are lack of standardization of  
assays  for HbA1c, false positive  and false negative results related to  
hemoglobinopathy and altered  red cell survival and  imperfect  correlation  
between   HbA1c  and  fasting and 2 hour plasma glucose. 
However HbA1c remains the preferred method for monitoring the  
effectiveness of diabetes treatment Kronenberg et al., 2008. 
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CRITERIA FOR DIAGNOSIS  OF  DIABETES: 
Test Normoglycemia 
(mg/dl) 
 IFG 
(mg/dl) 
IGT(mg/dl) Diabetes Mellitus 
FPG < 100 100-125  ≥126 
2-hour PG <140  140- 199 ≥200 
Casual  plasma 
glucose 
concentration 
   ≥200mg/dl  plus  
symptoms of diabetes 
Screening for Diabetes: 
Undiagnosed   diabetes is  more common with an estimate lag of  5  to 
7 years  between  the onset of diabetes  and diagnosis. It is estimated that in 
upto 30% of affected people  the disease  are undiagnosed. Subjects with 
undiagnosed Type 2 Diabetes Mellitus and IGT are in a greater risk of    
developing peripheral  vascular disease, stroke and  coronary artery disease  
in their later life. Thus, this delay in the diagnosis of diabetes causes an 
increase in microvascular and macrovascular complications Klein R et al., 
1992. 
              Impaired glucose tolerance or impaired fasting glucose sometimes   
referred to as “Pre-diabetes”. The blood glucose levels in prediabetic     
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individuals are greater than normal. Various studies have recommended      
that the  pre-diabetics should lose around 10% of  their  initial bod  weight 
otherwise they  are  prone to  develop diabetes  in  the  next 10 years. 
              In 2007,  data   from  American  health  department  revealed  that,    
around 57 million people are  coming   under  the  category  of  pre-diabetes.   
They  also  observed  that  one  in  4 adults above  the  age of  20 years are 
having pre-diabetes.
 
According to Chennai Urban Rural Epidemiology Study, as per the  
WHO  criteria, the  prevalence of  Impaired  Glucose Tolerance  was  around    
10%  and  that  of  diabetes was found to be around 15%.   
In  Chennai, there  is an escalating  prevalence of  Diabetes Mellitus    
during  the  past 14 years S Sandeep et al., 2011. 
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Period   of   Study Increase  in  prevalence of DM(%) 
1989 – 1995                                 40% 
1995- 2000                                   16% 
2000-  2004                                  6% 
3. Cerebrovascular accidents:  
The presence of metabolic syndrome has been associated with an 
increased risk of stroke. In the National Health and Nutrition Examination 
Survey, the prevalence of metabolic syndrome was significantly higher in 
persons with a self-reported history of stroke (43.5%) than in subjects with 
no history of vascular disease (22.8%) Ninomiya JK et al., 2004. Metabolic 
syndrome was independently associated with stroke history in all ethnic 
groups and in both sexes (OR, 2.16; 95% CI, 1.48 to 3.16). The association 
between metabolic syndrome and stroke has been confirmed in elderly 
population and the frequency of metabolic syndrome has been reported to be 
significantly higher in patients with a history of atherothrombotic or 
nonembolic ischemic stroke Milionis HJ et al., 2005. This association helps 
the clinical use of the metabolic syndrome in the identification of subjects 
who are at an increased risk of experiencing a stroke. 
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Long-term follow-up population-based studies have demonstrated that 
healthy individuals with the metabolic syndrome are at a markedly increased 
risk for major cardiovascular events including stroke McNeill AM et al., 
2005. In prospective studies, adjusted risk ratios for incident ischemic stroke 
associated with metabolic syndrome range from2.1 to 2.47 and a hazard ratio 
as high as 5.15 has been reported. This predictive capacity appears not to be 
influenced by the metabolic syndrome definition used and shows no 
significant variation across the sex, age or ethnic groups. The risk for 
incident ischemic stroke seems to increase with the increasing number of 
components of the metabolic syndrome, all of which are individually 
associated with an increased risk for future cerebral ischemic events Chen 
HJ  et al., 2006. 
      4. Nonalcoholic Fatty Liver Disease(NAFLD): 
Fatty liver is relatively common. Non- alcoholic fatty liver disease is 
often associated with features of the metabolic syndrome carrying an 
increased risk for the development of non-alcoholic steatohepatitis (NASH), 
the inflammatory form of liver steatosis. Data from epidemiological study 
confirm that obesity, diabetes, hypertension and dyslipidemia are frequently 
found in NAFLD and worsen its prognosis because of increased risk of 
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fibrotic evolution eventually leading to liver cirrhosis. As the prevalence of 
overweight/obesity and the metabolic syndrome increases, NASH may 
become one of the more common causes of end-stage liver disease and 
hepatocellular carcinoma. 
5.Chronic kidney disease 
 People with metabolic syndrome have a 55% increased risk of 
developing renal disorders especially lower kidney function, indicative of 
kidney disease. Kidney disease risk increases as the number of metabolic 
syndrome components increases. 
Hoehner et al., 2002 correlated the metabolic syndrome profile and 
microalbuminuria in a crosssectional study of American Indians from 
Wisconsin and Minnesota. Individuals with three or more metabolic 
syndrome traits had a 2.3-fold increased odds of having microalbuminuria 
compared with a control group without the syndrome. 
Palaniappanet al., 2004 found a statistical association between 
metabolic syndrome and microalbuminuria. Also discovered a significant 
correlation between number of metabolic syndrome factors and GFR. 
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Individual traits that confer greatest risk were hypertension and 
hyperglycemia. 
6.Polycystic Ovary Syndrome (PCOS) 
 Many patients with PCOS also have features of the metabolic 
syndrome which includes insulin resistance, obesity and dyslipidemia, 
suggestive of an increased risk for cardiovascular disease. Increased 
awareness of this overlap advocates therapies that improve insulin resistance 
and often ameliorate PCOS symptoms. This is one condition commonly 
detected in a younger age group and associated with a high risk of 
progression to diabetes. 
PCOS is highly associated with the metabolic syndrome with a 
prevalence between 40 and 50%. Women with PCOS are 2–4 times more 
likely to have the metabolic syndrome than are women without PCOS. 
Unlike the metabolic syndrome with its largely asymptomatic risk 
factors, PCOS occurs with overt symptoms like infertility, hirsutism and 
acne. Eventhough these are the problems that bring women to the attention  
of health care providers, their presence affords the opportunity to intervene 
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early with counselling and if needed, medications to modify the risk profile 
for later development of the metabolic syndrome or cardiovascular disease. 
7. Obstructive Sleep Apnoea 
The combination of metabolic syndrome and obstructive sleep apnoea 
has been termed “Syndrome Z”. The prevalence of both obstructive sleep 
apnoea and metabolic syndrome are increasing worldwide which is linked to 
the epidemic of obesity. Apart from their epidemiologic relationship, 
growing evidence suggests that obstructive sleep apnoea may be related to 
metabolic syndrome.  
Obstructive sleep apnoea is associated with alterations in the HPA 
axis that may promote metabolic syndrome. The hypoxia associated with 
obstructive sleep apnoea seems to trigger an oxidative stress that may 
promote development of metabolic syndrome. Several inflammatory 
markers and mediators including CRP, TNF-α and IL-6 are elevated in 
patients with obstructive sleep apnoea and may play a role in the 
development of metabolic syndrome. The adipokines like leptin, ghrelin and 
adiponectin are dys-regulated in patients with obstructive sleep apnoea in 
ways that promote a positive energy balance, obesity and metabolic 
syndrome. Sleep deprivation from obstructive sleep apnoea may also be 
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implicated due to its effects on both metabolic regulation and systemic 
inflammation. Acute sleep deprivation is associated with altered glucose 
homeostasis resulting in high blood glucose levels, insulin resistance and 
risk of diabetes. Identification of mechanistic interactions between 
obstructive sleep apnoea and metabolic syndrome may suggest opportunities 
by which the pathophysiology of obstructive sleep apnoea can be interrupted 
to prevent manifestations of the metabolic syndrome. 
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TREATMENT: 
The National Cholesterol Education Programme (NCEP) Adult 
Treatment Panel (ATP) III defined the criteria for the diagnosis of the 
metabolic syndrome and established the basic principles for its management. 
According to this, treatment involves correcting the underlying insulin 
resistance through lifestyle modification (eg, weight reduction and increased 
physical activity) and possibly by drugs. The coexistent risk factors (mainly 
dyslipidemia and hypertension) should also be addressed. 
Goals of Treatment 
The major goal of treating metabolic syndrome is to reduce the risk 
of cardiovascular disease. Treatment is directed first at lowering LDL 
cholesterol and high blood pressure and managing diabetes (if these 
conditions are present). 
The second goal of treatment is to prevent the onset of Type 2 
Diabetes Mellitus (if it hasn't already developed). If diabetes is present, the 
goal of treatment is to reduce your risk of the long-term complications which 
includes heart and renal disease, vision loss and foot or leg amputation. 
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Healthy lifestyle changes are the first line of treatment for metabolic 
syndrome. Lifestyle changes include losing weight, being physically active, 
taking a healthy diet and to quit smoking. 
Lifestyle Changes 
Losing Weight 
The long-range target is to lower the body mass index (BMI) to < 25. 
With weight reduction, the improvement in insulin sensitivity is often 
accompanied by favourable modifications in many components of the 
metabolic syndrome. In general, recommendations for weight reduction 
include a combination of caloric restriction in diet, increased physical 
activity and behaviour modification. 
Losing visceral fat 
 The following recommendations have been recognized as being 
helpful in reducing levels of visceral fat. 
 Regular exercise 
 Healthy, balanced diet 
 Good night's sleep 
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 Reducing stress level 
 Limiting alcohol intake 
 Quitting smoking 
Harvard University states that diet and exercise are found to be more 
effective at reducing visceral fat than the fat around the hips and thighs. 
When people slim down through exercise and diet, visceral fat reduces twice 
as fast as subcutaneous fat. 
 A research study, published in 2011 by Newcastle University, 
reported that a very low calorie diet can significantly reduce levels of 
visceral fat in people with Type 2 Diabetes Mellitus. Along with the 
reduction in visceral fat, the study participants showed improved blood 
glucose levels and a number of them were able to reduce or come off their 
diabetes medication. 
Following a  Healthy Diet 
A heart healthy diet is an important part of a healthy lifestyle  
A healthy diet includes  
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1. A variety of vegetables and fruits. A good rule is to try to fill half of 
your plate with vegetables and fruits. 
2. A healthy diet also includes whole grains, low-fat dairy products and 
protein foods, such as lean meats, seafood, soy products nuts, seeds, 
beans and peas. 
3. Choosing and preparing foods with little sodium (salt). Too much of 
salt can raise the risk for high blood pressure.  
4. Avoiding foods and drinks that are high in added sugars. For example, 
taking water instead of sugary drinks like soda. 
5. Avoiding high consumption of alcohol since it adds extra calories, 
which can cause weight gain. 
Studies comparing ethnically similar populations exposed to different 
dietary environments suggested that Westernized diets are strongly 
associated with a higher risk of developing metabolic syndrome. On the 
other hand, diets rich in dairy, fish and cereals may be associated with a 
lower risk of developing metabolic syndrome Ruidavets JB et al., 2007. 
Being Physically Active 
Exercise is thought to be an important intervention Roberts CK et al., 
2013.The current recommendation for patients is to perform regular 
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moderate-intensity physical activity for at least 30 minutes continuously at 
least 5 days per week (ideally, 7 days per week). However maintaining long-
term adherence remains a challenge Fappa E et al., 2007.A study by 
Bateman et al., 2011 concluded that aerobic training is the most efficient 
mode of exercise for improving the health. 
In one prospective study, cardiorespiratory fitness was linked to the 
risk of developing metabolic syndrome in a dose-dependent manner with 
patients in the highest category of fitness having the lowest risk of 
developing new-onset metabolic syndrome Shuval K et al., 2012. 
Evidence suggests that excessive sitting and other behaviours that are 
low in activity and energy expenditure may trigger unique cellular responses 
that contribute to the development of metabolic syndrome. 
Smoking 
Quit smoking. Smoking can raise the  risk for heart disease and heart 
attack. Smoking cessation can be achieved with or without assistance from 
healthcare providers or the use of medications. However, a combination of 
personal efforts and medications proves more effective to many smokers. 
Methods that are found to be effective include interventions directed at or 
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via health care providers and health care systems; medications including 
nicotine replacement therapy (NRT), individual and group counselling. 
Several hospitals, workplaces and community groups offer classes to 
help people quit smoking. 
MEDICATIONS: 
If lifestyle changes are not enough, medicines are used to treat and 
control risk factors such as high blood pressure, high triglycerides, low HDL 
cholesterol and high blood sugar. 
LDL Cholesterol 
According to NCEP:ATPIII, for patients with the metabolic syndrome 
and diabetes, LDL cholesterol should be reduced to <100 mg/dl and perhaps 
further in patients with a history of cardiovascular disease. 
Diets restricted in saturated fats (<7% of calories), trans-fats (as few 
as possible), and cholesterol (<200 mg daily) should be applied aggressively. 
If LDL cholesterol remains above goal, pharmacologic intervention is 
needed. 
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Statins (HMG-CoA reductase inhibitors) which produce a 20–60% 
lowering of LDL cholesterol are usually the first choice for medication 
intervention. Fibrates are best employed to lower LDL cholesterol when 
both LDL cholesterol and triglycerides are elevated.  
Triglycerides 
A fasting triglyceride value of <150 mg/dl is recommended. 
Generally, the response of fasting triglycerides relates to the amount of 
weight reduction achieved. A weight reduction of >10% is necessary to 
lower fasting triglycerides. 
A fibrate (gemfibrozil or fenofibrate) is the drug of choice to lower 
fasting triglycerides and typically achieve a 35–50% reduction. Other drugs 
that lower triglycerides include statins, nicotinic acid and high doses of 
omega-3 fatty acids. 
HDL Cholesterol  
Beyond weight reduction, there are very few lipid-modifying 
compounds that increase HDL cholesterol. Nicotinic acid is the only 
currently available drug with predictable HDL cholesterol-raising properties. 
The response is dose-related and can raise HDL cholesterol ~30% above 
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baseline. There is limited evidence at present that raising HDL has a benefit 
on cardiovascular events independent of lowering LDL cholesterol mainly in 
patients with the metabolic syndrome. 
Blood Pressure 
 Treatment of hypertension had been based on the recommendations of 
the Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure (JNC-7) 
guidelines, to attain a goal, blood pressure of less than 140/90 mm Hg or, 
less than 130/80 mm Hg in patients meeting diagnostic criteria for Diabetes 
Mellitus. 
In patients with the metabolic syndrome without diabetes, the first 
choice of antihypertensive should usually be an angiotensin-converting 
enzyme (ACE) inhibitor or an angiotensin II receptor blocker, because these 
two classes of drugs reduce the incidence of new-onset Type 2 Diabetes 
Mellitus. In all hypertensive patients, a sodium-restricted diet enriched with 
fruits and vegetables and low-fat dairy products should be advised. Home 
monitoring of blood pressure may help in maintaining good blood pressure 
control. 
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Impaired Fasting Glucose (IFG) 
 In patients with the metabolic syndrome and Type 2 Diabetes Mellitus 
aggressive glycemic control will favourably modify fasting triglycerides 
and/or HDL cholesterol. In patients with IFG without a diagnosis of 
diabetes, a lifestyle modification that includes weight reduction, dietary 
caloric restriction and increased physical activity has been shown to reduce 
the incidence of Type 2 Diabetes Mellitus. Metformin has also been shown 
to decrease the incidence of diabetes but the effect was less than that seen 
with lifestyle intervention. 
Insulin Resistance 
 An insulin-sensitizing agent such as metformin is typically used as a 
first drug in the treatment of patients with metabolic syndrome. Few 
literature suggests that metformin help to reverse the pathophysiological 
changes of metabolic syndrome. Several drugs such as biguanides, 
thiazolidinediones increase insulin sensitivity. Both metformin and 
thiazolidinediones enhance insulin action in the liver and suppress 
endogenous glucose synthesis. Thiazolidinediones but not metformin has 
been found to improve insulin-mediated glucose uptake in muscle and 
adipose tissue. Both the drugs also have beneficial effects in patients with 
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NAFLD and PCOS and the drugs have been shown to reduce markers of 
inflammation and small dense LDL. 
Cardiovascular complications 
Aspirin may contribute to the primary prevention of cardiovascular 
complications in metabolic syndrome mainly in patients with at least an 
intermediate risk of suffering a cardiovascular event (ie, >6% 10-y risk). 
Low-dose aspirin can help reduce the risk of blood clots particularly for 
people in whom risk of heart disease is high Blaha MJ et al., 2008. 
Surgical considerations 
At present no surgical interventions for metabolic syndrome have 
been widely accepted. Yet, trials of bariatric surgery in patients who were 
morbidly obese and had metabolic syndrome showed beneficial results 
including decrease in insulin resistance and lower levels of inflammatory 
cytokines. 
Visceral fat around abdominal organs cannot be liposectioned. 
Liposuction surgery removes only the subcutaneous fat. Risk factors 
including high blood pressure, hypercholesterolemia  and insulin resistance 
are not improved with loss of subcutaneous fat. 
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Importantly, metabolic syndrome raises specific perioperative issues 
that should be considered in patients with metabolic syndrome undergoing 
any major surgical procedure Bagry HS et al., 2008. 
Treatment of obstructive sleep apnoea syndrome 
Treatment of associated obstructive sleep apnoea may play a 
significant role in the management of metabolic syndrome Drager LF et al., 
2013. In a 2011 study, patients with moderate obstructive sleep apnoea who 
used continuous positive airway pressure (CPAP) therapy for 3 months 
showed significant improvements in their metabolic profile including 
reduction in blood pressure, LDL-cholesterol, triglycerides and glycated 
hemoglobin levels. Moreover, reversal of metabolic syndrome occurred to a 
greater degree in the CPAP therapy group than in patients who underwent 
treatment (13% vs 1%, respectively) Sharma SK et al., 2011. 
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MATERIALS AND METHODS 
Design of  the study: 
It is a cross sectional  study. 
Place  of  study: 
The study was conducted in Jeyavilas bus depot, Madurai. 
Collaborating Department : 
Department of Biochemistry, Madurai Medical College, Madurai. 
Study  subjects: 
A total of 100 subjects in the age group of 25 to 60 years were  
selected from Jeyavilas bus depot, Madurai. 
Inclusion criteria: 
Men who were drivers by occupation for > 5 years with minimum 8 
hours of driving per day. 
Age group 25-60 years. 
Exclusion  criteria: 
Females. 
Endocrine disorders like – Hypothyroidism, Cushing‟s disease. 
Chronic renal disease. 
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On medication – Steroid, Beta blokers, Thiazides etc. 
Ascites. 
Materials used for study: 
1.Proforma – to record the anthropometric measurements  of  the subjects 
and the clinical findings.  
2.Perceived stress scale 10 (PSS 10)  questionnaire  in Tamil –  to  assess  
the stress level. 
3.Portable weighing  machine – to record  the body weight in kilograms. 
4.Stadiometer – to measure the standing height in centimeters. 
5.Non  elastic   inch  tape -  to measure Waist circumference and Hip 
circumference in centimeters. 
6. Standardized mercury sphygmomanometer – to record the Blood Pressure 
in mm of Hg. 
7. EM 360   Fully  Automated   analyzer -  for   estimating   plasma  glucose  
and  lipid  profile. 
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METHODOLOGY: 
          The study was  initiated   with  the  approval  of  Institutional ethical 
committee, Madurai Medical College, Madurai. The  study was carried      
out  after  explaining  the  procedures in detail and getting  written  informed    
consent from  the subjects.  
The  experimental  protocol includes, 
1) Recording of a detailed  history  including  family history  of    
Cardiovascular   disease, Hypertension, Diabetes Mellitus,  history   of 
smoking, alcohol consumption, physical activity and  number of years 
spent in driving as an occupation. 
2) Perceived stress level was assessed using a standard questionnaire- 
Perceived stress scale 10 (PSS 10). Subjects were asked to fill up the 
PSS 10 questionnaire. 
3) Measurement of Anthropometric Indices:   
 
The subjects were asked to stand  erect, with their arms relaxed  at    
their side and with feet together. 
Weight (in kilograms) was   recorded  using a portable standard  weighing 
machine. Weight was measured to the nearest 0.5 kg in subjects wearing    
inner  clothing   and  without   shoes after they had emptied their pockets. 
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Height (in centimeters) was measured  to the  nearest  0.5 cm by 
asking the patient to stand erect without  shoes and the vertical height was 
measured  using  a  stadiometer.  
Body Mass Index ( BMI) was  computed  as the weight in  kilograms 
divided by the  square of  the height  in meters using Quetelet‟s Index. 
            BMI =   Weight  (Kg)/ Height  (m
2
). 
Waist circumference was measured  to  the nearest 0.5 cm  with  an         
inch tape at the point midpoint between the lower rib margin and the iliac 
crest at the end of  normal  expiration with the subject in standing   position. 
 According  to the National Cholesterol   Education  Programme Adult    
Treatment Panel III (2001)Waist circumference ≥  90 cm in males,   ≥ 80 cm 
in females is considered  as central  obesity. 
1) Measurement of  Blood pressure: 
      Documentation  of  blood pressure  was done  using  the  standard  
sphygmomanometer with cuff size 25×12.5cms. Before taking    
measurement the subject  was  seated  quietly for 15  minutes in a quiet  
room  with  a comfortable  room   temperature. For final  analysis,  the mean 
value of the two blood  pressure  recordings obtained  at  5 minutes  interval 
from the  left  arm  of  the subjects in the sitting  posture is  taken.   
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2) Blood investigations: 
After an overnight fasting for 8-10 hours blood sample was collected. 
The following investigations were done : 
For venous blood collection antecubital vein of front of forearm was 
selected. Skin is sterilized over the vein with a spirit cotton swab. A 
disposable sterile needle fixed to a disposable syringe of 10ml capacity and 
the desired amount of blood was collected.  
1. Fasting Plasma Glucose. 
       For separation of serum, blood taken into a plain vial is first allowed to 
clot and then centrifuged at 3000 rpm for 5 minutes. 
This separated serum was used to estimate: 
2.HDL cholesterol 
3.Triglycerides 
COLLECTION   OF   BLOOD SAMPLE 
Fasting   plasma  sugar   was   estimated    by    glucose    oxidase 
peroxidase    (GOD-POD)   method. 
Serum HDL - cholesterol    and   Triglycerides were measured     by    direct     
enzymatic     method    using an auto-analyser (ERBA-XL-300). 
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ESTIMATION OF TRIGLYCERIDES: 
METHOD: GPO-PAP method, endpoint 
METHODOLOGY: 
Colorimetric, enzymatic method with glycerol phosphate oxidase. 
PRINCIPLE: 
Triglycerides + H2O                    Glycerol + free fatty acids 
 
Glycerol + ATP            Glycerol 3 phosphate + ADP 
 
Glycerol 3 phosphate + O2                 DAP + H2O2 
 
H2O2 + 4AAP+3,5-DHBS                                 Quinoneimine dye + 2H2O 
LPL- Lipoprotein lipase 
GK- Glycerol kinase 
GPO- Glycerol Phosphate Oxidase 
DAP-Dihydroxy Acetone Phosphate 
  LPL 
GK 
 
GPO 
PEROXIDASE 
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ATP- Adenosine Tri Phosphate 
4AAP- 4Amino Anti Pyrine 
DHBS-3,5Dichloro-2Hydroxy Benzene Sulfonate 
Lipoprotein lipase catalyzed hydrolysis of triacylglycerol yield 
glycerol which is phosphorylated by  glycerol  kinase  using  ATP  to 
glycerol-3-phosphate  which  upon  oxidation  yields  dihydroxy acetone 
phosphate and hydrogen peroxide. The hydrogen peroxide reacts with 
phenolic compound and 4amino antipyrine to form a coloured complex.    
The intensity of Quinoneimine dye formed is proportional to the triglyceride 
concentration in the sample when measured at 505 nm (500-540nm). 
REAGENT: 
     Reagent 1 (Enzymes/chromogen) 
     Reagent 2 (Buffer) 
     Triglycerides standard concentration- 200mg/dl 
REAGENT PREPARATION: 
 The working reagent was prepared by mixing 4 parts of  R1 with 1 
part of R2. Stable for 90 days at 2-8 
◦
C.  
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Sample: Unhemolysed serum collected after 12 hours of fasting. 
ASSAY PROCEDURE: 
Pipette into tubes 
marked 
Blank Standard Test 
Working reagent 1000µl 1000µl 1000µl 
Distilled water 10µl - - 
Standard - 10µl - 
Sample - - 10µl 
 
Mixed and incubated for 10minutesat room temperature. Absorbance  
were read at 505nm for standard and sample against reagent blank. 
CALCULATION: 
Triglycerides(mg/dl)      =  Absorbance of test      x   Concentration of standard  
   Absorbance of standard 
REFERENCE VALUES: 
Serum/plasma 37
◦
C 
Normal fasting level 25-160mg/dl 
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Linearity – upto 1000mg/dl 
Sensitivity- 2mg/dl 
ESTIMATION OF HDL CHOLESTEROL: 
 METHOD: Phosphotungstic acid method, endpoint 
PRINCIPLE: 
 Chylomicrons(CM), LDL and VLDL are precipitated from serum or 
plasma with phosphotungstate in the presence of divalent cations such as 
Magnesium. The HDL cholesterol remains unaffected in the supernatant and 
is estimated using cholesterol reagent.                        
Serum/plasma                                             HDL      +     (LDL+VLDL+CM) 
                  (supernatant)     (precipitate) 
REAGENT COMPOSITION: 
Reagent1: precipitating reagent 
Phosphotungstic acid 2.4mmol/l 
Magnesium chloride 40mmol/l 
 
Phosphotungstic acid, Mg
2+ 
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HDL cholesterol standard – 25mg/dl 
SAMPLE: Unhemolysed serum used 
PRECIPITATION: 
Precipitation of LDL,VLDL  and Chylomicrons done as follows: 
 
 
 
Mixed well and the reaction mixture was allowed to stand for 10 
minutes at room temperature centrifuged at 4000 rpm for 10minutes and 
obtain a clear supernatant solution. The supernatant was used to determine 
the concentration of HDL cholesterol in the sample. 
ASSAY PROCEDURE: 
Pipette Volume 
Sample 250µl 
Precipitating reagent 500µl 
Pipette into tubes marked Blank Standard Test 
Cholesterol working reagent 1000µl 1000µl 1000µl 
Distilled water 50µl - - 
HDL standard - 50µl - 
Supernatant - - 50µl 
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Mixed well and incubated for 10 minutes at room temperature. 
The absorbance of the standard and the test samples were read at 505 
nm against reagent blank. 
CALCULATION 
HDL cholesterol (mg/dl)=Absorbance of test      x  conc.of standard x dilutionfactor 
 Absorbance of standard                                           
      =    Absorbance of the test           x 25 x 3 
         Absorbance of the standard  
      =    Absorbance of the test           x 75 
                                        Absorbance of the standard 
Linearity- upto 125mg/dl. 
ESTIMATION OF GLUCOSE: 
METHOD: Glucose oxidase- peroxidase method, end point/fixed time. 
PRINCIPLE: Glucose in the sample is oxidized to yield gluconic acid and 
hydrogen peroxide in the presence of glucose oxidase. The enzyme 
peroxidase catalyses oxidative coupling of  4 –amino antipyrine  with phenol 
to yield a coloured quinoneimine complex with absorbance proportional to 
the concentration of glucose in the sample. 
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                               Glucose oxidase 
Glucose + O2 + H2O                            Gluconicacid + Hydrogen peroxide 
 
  Peroxidase 
H2O2 + Phenol+4 AAP                              Quinoneimine dye + 2 H2O2 
 
Glucose standard : 100mg/dl 
Specimen: Fresh unhemolysed serum used. 
ASSAY PROCEDURE: 
Enzyme reagent 1ml 1ml 1ml 
Blank 10µl -  
Standard - 10µl - 
Test - - 10µl 
 
Mixed well after  each addition and incubated at 37
◦
C for 5 minutes. 
The absorbance of the standard and the test were read against reagent blank 
at 505nm. 
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CALCULATION: 
Glucose (mg/dl) =   Absorbance of test        x concentration of standard (100mg/dl) 
                                Absorbance of standard  
Linearity upto 500mg/dl by endpoint method. 
NORMAL VALUES:     
- Glucose fasting= 70-110 mg/dl 
- Glucose postprandial= 90-140 mg/dl. 
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RESULTS AND OBSERVATION 
STATISTICAL ANALYSIS 
The association between the risk factors and the outcome variables 
was analysed using Pearson‟s Chi Square test. The statistical analysis was 
done using SPSS (Statistical Package for Social Sciences) software 
version 21. The statistical significance was drawn at „p‟ value < 0.05. „p‟ 
value <0.05 was considered as statistically significant. 
 Table-1: Association of influence of BMI with the occurrence of 
metabolic syndrome among occupational drivers 
 
 
 
 
S.No 
 
BMI (kg/m
2
) 
            Presence of  MetS  
„p‟ value No   Yes  
 
1 
 
< 18.5 
 
32 
 
1 
 
 
 
< 0.001 
 
2 
 
18.5-24.9 
 
19 
 
4 
 
3 
 
25-29.9 
 
14 
 
13 
 
4 
 
≥ 30 
 
2 
 
15 
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When comparing the occurrence of metabolic syndrome with BMI, 
there was a significant increase in the occurrence of metabolic syndrome as 
the BMI increases.  
Results analysed using Pearson‟s Chi Square test revealed a 
statistically very significant „p‟ value (p <0.001). 
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Table-2: Association of influence of stress with the occurrence of 
metabolic syndrome among occupational drivers 
 
 
S.No 
 
PSS 10 score 
            Presence of MetS  
„p‟ value No   Yes  
 
1 
 
≤ 12 
 
26 
 
8 
 
 
 
     0.001 
 
2 
 
13-23 
 
33 
 
10 
 
3 
 
24-29 
 
8 
 
15 
 
When comparing the occurrence of metabolic syndrome with stress 
level using Perceived Stress Scale (PSS 10), there was a significant increase 
in the occurrence of metabolic syndrome as the stress level increases.  
Results analysed using Pearson‟s Chi Square test revealed a 
statistically very significant „p‟ value (p 0.001). 
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Table-3: Association of influence of smoking with the occurrence of 
metabolic syndrome among occupational drivers 
 
 
S.No 
 
History of smoking  
            Presence of MetS  
„p‟ value No   Yes  
 
1 
 
No  
 
46 
 
13 
 
 
    0.005  
2 
 
Yes  
 
21 
 
20 
 
When comparing the occurrence of metabolic syndrome with 
smoking, there was a significant increase in the occurrence of metabolic 
syndrome in smokers than in non smokers.  
Results analysed using Pearson‟s Chi Square test revealed a 
statistically significant „p‟ value (p 0.005). 
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Table-4: Association of influence of alcohol consumption with the 
occurrence of metabolic syndrome among occupational drivers 
 
 
S.No 
History of alcohol 
consumption 
            Presence of MetS  
„p‟ value No   Yes  
 
1 
 
No  
 
41 
 
15 
 
 
    0.136  
2 
 
Yes  
 
26 
 
18 
 
When comparing the occurrence of metabolic syndrome with alcohol 
intake, there was no significant difference in the occurrence of metabolic 
syndrome in person who take alcohol and those who do not take alcohol.  
Results analysed using Pearson‟s Chi Square test revealed a 
statistically insignificant „p‟ value (p 0.136). 
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Table-5: Association of influence of duration of service with the 
occurrence of metabolic syndrome among occupational drivers 
 
 
S.No 
Duration of service 
     (yrs) 
            Presence of MetS  
     „p‟ value No   Yes  
 
1 
 
5-9 
 
29 
 
4 
 
 
 
<0.001 
 
2 
 
10-19 
 
20 
 
6 
 
3 
 
20-29 
 
13 
 
10 
 
4 
 
≥30 
 
5 
 
13 
 
When comparing the occurrence of metabolic syndrome with duration 
of service, there was a significant increase in the occurrence of metabolic 
syndrome as the duration of service increases.  
Results analysed using Pearson‟s Chi Square test revealed a 
statistically very significant „p‟ value (p <0.001). 
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DISCUSSION 
 In the past few years growing attention has been paid to the 
metabolic syndrome since early reorganization can prevent from its 
complications. However to date, data on its occurrence and the underlying 
risk factors are very limited among occupational drivers. Therefore the 
purpose of this study is to evaluate the occurrence of metabolic syndrome 
and to assess its risk factors among this special occupational group. 
According to Moreno et al., 2004 this category of workers in Brazil 
has a higher chance of obesity, physical inactivity, unhealthy diet, smoking 
habits, high levels of cholesterol, hypertension and obstructive sleep apnoea 
in comparison to the general population in Brazil. 
 In India very  few  studies  had  been  done  to  find  the prevalence    
of  metabolic  syndrome  and  most   of   the   studies  which  are  available  
in  literature  had  used  ATP-III. But Deepa et al.,2006 compared   the  
prevalence of metabolic syndrome in  South  Indian population   by  various  
definitions and  found  that  by  IDF 25.8% individuals more  than  20 years 
of  age were having metabolic  syndrome  as compared  to  18.3%  by  ATP-
III.   
Higher  prevalence by  using   IDF  criteria can be explained by the 
lower cut-off  points adopted  by this  new definition. In IDF criteria,   
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central obesity is the major criterion, its cut –off  is ethnicity specific and is 
lower for Indians than used by original ATP-III. Another difference    
between  two  definitions is lower  cut  off   for  fasting  blood  sugar  by    
IDF,  which  is >100  mg/dl as compared  to >110 mg/dl in ATP-III.  The   
higher prevalence by new IDF definitions is comparable with  other  reports.  
The  present   study   shows   the occurrence   of   metabolic syndrome  
to about  33%  of   the   study  population, which reveals higher prevalence 
of metabolic syndrome than that of the general population. In a cross 
sectional study, among drivers in the central part of Iran, 35.9% of the 
participants suffered metabolic syndrome based on ATP III criteria Saberi 
HR et al., 2011. In a comparative study done in Norway on cardiovascular 
risk factors among bus drivers and industrial workers, the results showed 
that bus drivers had higher mean values of serum cholesterol level, serum 
triglycerides level, systolic and diastolic blood pressure. 
Smoking and obesity are the main causes of preventable morbidity 
and mortality in developed countries Ezzati Met al., 2004. 
Obesity is due to combination  of inadequate  exercise,  high  caloric    
diet,  inadequate  physical   activity  and  genetic  predisposition. 
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          In developing countries like India, obesity affects most of the adults 
and children resulting in many public health problems. The prevalence of 
obesity is around 15%  of children in  U.S. 20% of children in Australia and 
14% of children in  Egypt.
 
The reason why bus driver showed high BMI (BMI ≥ 25 kg/m2) and 
waist circumference (WC ≥ 90cm) is due to their irregular eating habits and 
low physical activity rates due to sitting on the job. As abdominal visceral 
adipose tissue increases, blood glucose and TG increases, HDL decreases 
and hypertension or diabetes increases Liu JK et al., 2010. 
The present study reveals that occupational drivers are more prone for 
obesity. This category is more in drivers with metabolic syndrome. High 
BMI contributed significantly towards the development of metabolic 
syndrome. The study carried out by Shakhatreh et al., 2000 in Saudi Arabia 
concluded that 73.2% of the drivers were obese. In Taiwan, obesity was seen 
in 9.6% of  2297 bus drivers while 4.6% for the workers. In Poland, obesity 
in drivers was 17.4%. In another study conducted in Mexico on professional 
drivers, it was found that the prevalence of obesity and overweight was 22.5 
and 52.7%, respectively, which was higher than the general population of 
Mexico. 
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A study carried out in the United States involving more than 600 
thousand workers found the highest prevalence of obesity to be among male 
employees who work in highway transportation services (31.7%). A study 
involving a representative sample of the Australian in productive age 
compared ten different functional categories with regard to the risk of 
obesity and found that male employees of the transportation industry had a 
higher risk of overweight and obesity Aguilar-Zinser JV et al., 2007.  
 Perceived stress, which measures the degree to which a person 
appraises situations in his or her life as stressful is one of several 
psychosocial factors related to work-related stress Cohen S et al., 1983. 
Perceived work stress has been linked with CVD as well as components  of 
the metabolic syndrome Rosmond R et al., 2000. Chronic stress is 
associated with  an increased risk of the metabolic syndrome and can be an 
underlying cause of the metabolic syndrome by dysregulating the HPA axis 
Gohil B et al., 2001. 
 Hills and Norvell suggested that the PSS is a significant and 
important predictor of stress-induced consequences including exhaustion,  
physical symptoms and job dissatisfaction in highway patrol officers. 
Franke et al., 2002 found that high PSS was associated with cardiovascular 
disease risk. In contrast, however, Yoo and colleagues found that the PSS 
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was not significantly associated with the metabolic syndrome (r = 
0.047).Therefore, chronic stress at work is an important risk factor for the 
metabolic syndrome.  
Franke and colleagues found that higher levels of perceived stress 
are directly associated with increased cardiovascular disease prevalence, in 
addition to increased prevalence of dyslipidemia , hypertension  and physical 
inactivity. Recent studies also suggest that stress at work may influence the 
pathogenesis of the metabolic syndrome.  
Chandola and coworkers conducted a prospective cohort study with 
an average of 14 years of follow-up on 10,308 men and women. This study 
found that employees with chronic work stress are more than twice as likely 
to have the metabolic syndrome than those without stress at work, after 
controlling for age and employment grade (odd ratio [OR] = 2.25, 95% CI = 
1.31 – 3.85). 
 Working environment of drivers may also play a role in 
developing metabolic syndrome.  
In the present study, analysis revealed smoking to contribute 
significantly to the development of metabolic syndrome. Compared with 
nonsmokers, active smokers usually have more severe insulin resistance and 
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hyperinsulinemia which can increase the risk of Type 2 Diabetes Mellitus 
He Y et al., 2009. 
Several studies have also shown that smoking is associated with 
metabolic abnormalities and increases the risk of metabolic syndrome 
Nakanishi et al., 2005. This study reported that subjects who habitually 
smoked tobacco had a 1.07–1.66 fold greater risk of developing metabolic 
syndrome than subjects who did not smoke. Weitzman et al., 2005 have 
demonstrated the relationship between tobacco smoke and the severity of 
metabolic syndrome. The authors reported that exposure to tobacco smoke, 
either active or passive smoking  is associated with a fourfold increase in the 
risk of the metabolic syndrome among adolescents who are overweight or at 
risk of overweight. Saarni et al., 2009 investigated the association between 
adolescent smoking and overweight or abdominal obesity in adulthood. The 
result is that smoking is a risk factor for abdominal obesity in both sexes and 
for overweight in women. 
Several earlier small-scale studies have reported smoking to be 
associated with higher prevalence of metabolic syndrome. The positive 
dose–response relationship between the amount of tobacco smoked and the 
prevalence of metabolic syndrome  that we observed is also consistent with 
previous studies Weitzman M et al., 2005. 
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 Some earlier epidemiologic studies relating alcohol 
consumption to the metabolic syndrome have lent data supporting that a 
minimal amount of drinking has protective effects on the prevalence of the 
metabolic syndrome compared with nondrinking Freiberg MS et al., 2004. 
By contrast, Fan et al., 2006 examined lifetime drinking pattern and found 
that the prevalence of the metabolic syndrome was directly increased with 
lifetime drinking intensity (total drinks/drinking days over lifetime).It has 
been suggested that 5 to 30 gm/day of alcohol consumption may be 
favourable for Type 2 Diabetes Mellitus. Observational studies have found 
an inverse association between alcohol consumption and glycemic control at 
least in part through enhanced insulin sensitivity Meyer KA et al., 2003. 
The study also observed that the metabolic syndrome components 
contributing to the increase are hypertension and an elevated concentrations 
of fasting glucose and triacylglycerols for both men and women and central 
obesity for women. Thus, suggesting that average moderate drinking over 
the lifetime does not have favourable effects on the metabolic syndrome.  
Because of the nature of their work, they are used to the habit of 
smoking and alcoholism. In the present study it is found that with an 
increase in the duration of service, there is an increase in the occurrence of  
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metabolic syndrome. This indicates the combined role of stress, sedentary 
life style and smoking with the occurrence of metabolic syndrome. 
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CONCLUSION  
Drivers sit for long hours and walk less compared to the general 
public. In addition, physical activity involvement and physical demands 
during the driving are usually limited and insufficient to maintain physical 
fitness. 
Studies in recent decades have demonstrated that workers in the 
transportation industry are at greater risk of an incorrect diet and sedentary 
behavior Bigert C et al., 2003. 
Our study showed  influences of  obesity, stress, smoking and alcohol 
consumption on  the occurrence  of   metabolic syndrome in occupational 
drivers. 
The most effective measures to improve insulin sensitivity in 
metabolic  syndrome  affected individuals   are   exercise  and  weight loss.  
Both  modalities  are  effective   and  can  be  additive   in  their  ability to 
improve  insulin action.   
“Regular  exercise”   is   required   for   healthy   aging!! 
Hence a motivation  a   minimum   of   three    exercise    training   
sessions   a  week  to   maintain   the   benefit  of  regular   physical activity 
is needed.  
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 Smoking subjects are at a high risk of developing the metabolic 
syndrome. Interventional studies offers support to smokers willing to quit 
through physical activity promotion and healthy diet in order to reduce 
smoking prevalence whereas avoid weight gain following cessation is a 
desirable public health goal.  
Various public  health  policies  should be  implemented   in  India, in  
order  to  control the alarming  rise  of  cardiovascular risks and  metabolic 
syndrome. 
Change in the lifestyle is the best way in the prevention of metabolic  
syndrome. 
 
 
 
 
 
 
 
 
 
 
106 
 
LIMITATION: 
The present study was a basic screening  of  individuals for  assessing  
the  contributors of metabolic syndrome. The other components including    
tumor necrosis  factor  -  alpha,   interleukin-6,  fibrinogen, plasma  insulin, 
C–reactive protein and others  would have  helped  in  better interpretation.   
A cohort  study  with   larger  sample  size   will  help in  assessing   
the  progression and  complications of  metabolic syndrome. 
Future  scope  of  present  study: 
 
The present study reflects the real burden of  metabolic syndrome in   
the special group of people  by  using   specific well  defined criteria  and     
laboratory  investigations. The individuals who are at high risk with family    
history of  hypertension, diabetes and dyslipidaemia once identified should 
start  medication. Those at low risk are recommended to increase their  
physical  activity   and   to have  high fiber diet. The need of the hour would 
be to increase the awareness of  etiological factors for metabolic  syndrome 
among the  general public. 
 In our population, it is essential to reduce the alarmingly 
increasing burden of metabolic syndrome by appropriate preventive  
measures.  More frequent assessments will be appropriate  for   follow up of  
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this  study which could reveal better changes in  various   components  of 
metabolic syndrome.   
 For high risk patients in cross sectional population and  in    
some specific  category  to identify the prevalence of metabolic  syndrome,   
it is necessary to conduct more  prospective  studies  in  other  regions of    
our country.   
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PROFORMA 
Name:       Age: 
Sex:        Occupation: 
H/O smoking:                           
No of cigarettes/day:    For how many years: 
H/O alcohol intake:  
Nil/occasionally/weekly/monthly. For how many years: 
Regular exercise:   
Time spent/day:    For how many years: 
Diet:             Vegetarian/Non vegetarian. 
Duration of sleep/day: 
Stress score as per PSS 10:  
Duration of service: 
Working hours/day: 
 
 
 
            Duration           On treatment 
 
H/O Diabetes:   
H/O Hypertension:   
H/O Hyperlipidemia: 
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H/O Angina:  
Family H/O Diabetes/Hypertension/Hyperlipedemia: 
Medications if any: 
Anthropometric measurements: 
Ht (cm):                  Wt (kg):             BMI(kg/m
2
): 
 Waist circumference (cm):  Waist hip ratio: 
General Examination: 
Consciousness:   Orientation: 
Comfortable at rest:  Pallor: 
Cyanosis:    Clubbing: 
Jaundice:    Pedal oedema: 
Thoracic/Spine deformity: 
JVP:     Generalized Lymphadenopathy: 
Temperature (
0
F):   Respiratory rate/min: 
Pulse rate/min:   Blood pressure (mmHg): 
CARDIOVASCULAR SYSTEM: 
 
RESPIRATORY SYSTEM : 
 
ABDOMEN                                : 
 
CENTRAL NERVOUS SYSTEM: 
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BIOCHEMICAL MEASUREMENTS:  
Fasting blood glucose level (mg/dl): 
Serum triglycerides (mg/dl): 
Serum HDL (mg/dl): 
மருத்துவப் பரிச ோதனை முனைகனைப்பற்ைி மருத்துவரிடம் ததரிந்து 
தகோண்சடன். இதனை சமற்தகோள்ை நோன் முழுமைதுடன்  ம்மதிக்கிசைன். 
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 Perceived Stress Scale – 10 
 
0xUNghJk; ,y;iy  1mNdfkhf ,y;iy 
2rpyNtisfspy;  3nghJthfmbf;fb4kpfmbf;fb 
 
1. fle;jkhjk; Vjpu;ghuhjtpjkhfele;jrk;gtq;fshy; vj;jidjlitfs; 
ftiyAw;wPu;fs;? 
 
 
2. fle;jkhjk; cq;fs; tho;f;ifapYs;sKf;fpakhdtpraq;fiscq;fshy; 
fl;Lg;gLj;jKbahky; ,Ue;jjhfvj;jidjlitfs; czu;e;jPu;fs;? 
 
 
 
3. fle;jkhjk; vj;jid jlitfs; glglg;Gld; 
$bakdcisr;riyczu;e;jPu;fs;? 
 
 
 
4. fle;jkhjk; cq;fs; jdpg;gl;lgpur;rpidfisr; 
rkhspf;fcq;fSf;Fkdj;ijupak; cs;snjdvj;jidjlitfs; czu;e;jPu;fs;? 
 
 
 
5. fle;jkhjk; ePq;fs; epidj;jJNghy; nray;fs; ahTk; 
eilngw;wdvdvj;jidjlitfs; czu;e;jPu;fs;? 
 
 
 
6. fle;jkhjk; cq;fshy; nra;ag;glNtz;bapUe;jvy;yhnray;fisAk; cq;fshy; 
<LnfhLf;fKbahky; Ngha;tpl;ljhfvj;jidjlitfs; czu;e;jPu;fs;? 
 
 
 
7. fle;jkhjk; vj;jidjlitfs; 
cq;fsf;Fvupr;rY}l;banray;fisfl;Lg;gLj;jf;$bajhf ,Ue;jJ? 
 
 
8. fle;jkhjk; vj;jidgpur;rpidf;Fupanray;fisKwpabj;jjhfczu;e;jPu;fs;? 
 
 
9. fle;jkhjk; cq;fspd; fl;Lg;ghl;bw;Fmg;ghw;gl;lnray;fshy; 
vj;jidjlitfs; Nfhgg;gl;Bu;fs;? 
 
 
10. fle;jkhjk; cq;fshy; ntw;wpnfhs;sKbahJnkd;NkYk; 
cau;e;Jnfhz;bUe;jgpur;rpidfshy; f\;lg;gl;ljhfvj;jidjlitfs; 
czu;e;jPu;fs;? 
 
 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
0 1 2 3 4 
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Apple shape Vs Pear shape 
 
 
 
 
 
 
 
  
 
 
 
 
Prevalence of the metabolic syndrome from ATP III definition 
 
 
 
 
 
 
 
  
 
Pathophysiology 
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drivers
BMI (kg/m2)
Presence of MetS
BMI Vs Metabolic syndrome
No Yes
  
 
 
 
 
 
 
 
 
 
 
 
 
 
46
21
13
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0
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No Yes 
No of drivers 
Smoking
Presence of MetS 
Smoking Vs Metaboilc syndrome
No Yes
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15
18
0
5
10
15
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No Yes
No of 
drivers 
Alcohol consumption
Presence of MetS 
Alcohol consumption Vs Metaboilc syndrome 
No Yes
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33
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15
0
5
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15
20
25
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<12 13-23 24-29
No of drivers
PSS 10 score
Presence of MetS 
Stress Vs Metabolic syndrome
No Yes
  
 
 
 
 
 
 
 
 
 
 
 
 
 
29
20
13
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6
10
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0
5
10
15
20
25
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35
5-9yrs 10-19yrs 20-29yrs ≥30yrs
No of drivers 
PSS 10 score
Presence of MetS
Duration of service Vs Metabolic syndrome
No Yes
  
 
 
AUTO ANALYSER ( ERBA – XL-300) 
 
 
 
 
 
 
 
 
 
  
COLLECTION OF BLOOD SAMPLE 
 
 
 
 
 
  
MEASUREMENT  OF BLOOD PRESSURE 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
                                           
S. 
No 
Name Age 
(yrs) 
Gen
der 
Duration 
of service 
(yrs) 
H/O 
smok
ing 
H/O 
Alcohol 
intake 
PSS 
10 
score 
Taking 
RX  for 
DM,HT 
HTG 
BMI 
kg/m
2
 
Waist  
cm 
 
B.P 
mmHg 
FBS 
mg/dl 
S.TGL 
mg/dl 
S.HDL 
mg/dl 
Presence of 
metabolic 
syndrome 
1 Boopathi 33 M 12 No Yes 29 DM,HT 40.7 126 140/90 96 186 32 Yes 
2 Manisekar 58 M 36 No Yes 25 DM 31.8 98 130/90 232 152 33 Yes 
3 Natarajan 46 M 21 Yes Yes 26 - 32.1 101 140/90 98 105 39 Yes 
4 Alagupandi 44 M 12 No Yes 16 - 17.3 76 120/70 105 142 38 No 
5 Anand 48 M 15 No Yes 22 DM 24.7 83 120/70 121 157 43 No 
6 Annamalai 56 M 33 No Yes 18 DM 17.8 92 120/70 116 75 50 No 
7 Antony Raj 52 M 30 No No 24 - 27 94 120/80 78 87 31 No 
8 Arun 37 M 8 Yes No 23 - 24.6 98 100/70 86 83 36 No 
9 Amaiah 48 M 19 Yes Yes 18 DM 27.7 92 120/70 91 119 51 No 
10 Balaji 46 M 11 Yes No 12 - 18.4 75 120/70 98 93 37 No 
11 BalaVenkatesh 38 M 5 Yes Yes 14 - 23.9 83 120/80 90 110 42 No 
12 Balu 45 M 15 Yes No 6 HT 30.5 101 160/110 130 186 40 Yes 
13 Arumugam 52 M 23 Yes Yes 24 DM,HT 23.3 91 120/80 101 90 24 Yes 
14 Chandrasekaran 36 M 16 No No 26 DM,HT 23.7 101 120/70 123 155 33 Yes 
15 Chandra sekar 36 M 8 No Yes 13 - 22.9 86 130/70 96 129 43 No  
16 Chidambaram 55 M 23 No No  12 HT 26.2 86 140/80 92 194 46 No 
17 Albert 36 M 13 No Yes 8 - 24.7 94 120/70 95 90 27 No 
18 George 55 M 22 No No  9 - 25.4 85 120/80 247 118 36 No 
19 Sundaramoorthy 43 M 22 Yes Yes 11 - 18.3 85 130/90 112 115 36 Yes 
20 Thangaraj 30 M 9 No  Yes 25 DM,HT 30.4 108 150/100 124 74 36 Yes 
21 Devaraj 35 M 9 No No  12 DM 26.6 94 120/80 104 106 36 No 
22 Kaliayamoorthy 40 M 21 Yes Yes 14 DM 26 100 120/80 102 76 36 Yes 
23 Raja 53 M 33 Yes No 26 DM,HT 26 99 130/90 115 125 36 Yes 
24 TamilSelvan 47 M 25 No No  26 - 18.3 96 110/70 123 92 44 No 
25 Ganesan 58 M 25 Yes Yes 27 DM 30.4 108 130/80 126 94 30 Yes 
26 Janakiraman 46 M 18 Yes Yes 8 HT 18.2 85 110/80 103 117 45 No 
27 PalaniSamy 54 M 32 Yes Yes 19 DM 27.7 101 120/80 109 298 33 Yes 
28 Devapragasam 49 M 27 No Yes 23 - 30.3 109 130/90 89 135 27 Yes 
                                           
S. 
No 
Name Age 
(yrs) 
Gen
der 
Duration 
of service 
(yrs) 
H/O 
smok
ing 
H/O 
Alcohol 
intake 
PSS 
10 
score 
Taking 
RX  for 
DM,HT 
HTG 
BMI 
kg/m
2
 
Waist  
cm 
 
B.P 
mmHg 
FBS 
mg/dl 
S.TGL 
mg/dl 
S.HDL 
mg/dl 
Presence of 
metabolic 
syndrome 
29 Doss 40 M 18 Yes No 19 HT,HTG 27.1 100 140/80 278 94 24 Yes 
30 Mageshwaran 50 M 24 No Yes 20 DM,HT 26.4 92 120/80 85 98 36 No 
31 Arivalagan 46 M 16 No Yes 13 - 17.2 72 100/70 88 87 28 No 
32 Chandramohan 45 M 13 Yes Yes 28 DM 21.6 90 130/80 103 180 35 Yes 
33 Chandran 41 M 7 No No  21 - 18.1 96 120/70 82 96 36 No 
34 PasilAhamed 51 M 32 Yes No 29 - 30 95 140/90 134 127 48 Yes 
35 Bala Raman 30 M 7 No Yes 11 - 18.4 80 120/80 125 159 52 No 
36 Kannan 53 M 31 No Yes 28 - 23.3 94 130/90 98 110 40 No 
37 Kannan 32 M 5 Yes No  18 - 18.3 97 130/90 91 126 45 No 
38 Kumar 41 M 17 Yes No  16 - 23.2 87 120/80 96 89 40 No 
39 Muruganantham 56 M 35 No Yes 12 HT 25.4 95 140/80 70 84 24 Yes 
40 Murugesan 47 M 11 No No 28 - 31.4 105 130/90 86 86 45 No 
41 Pandian 54 M 32 No No  14 HTG 20.5 88 120/80 71 123 39 No 
42 Paul Raj 58 M 25 No No  23 - 18.4 86 130/70 96 129 43 No 
43 Radha Krishnan 57 M 35 No No 21 DM 31.4 99 150/100 116 128 30 Yes 
44 Raman 36 M 5 No No 22 - 22.6 98 120/70 77 90 44 No 
45 Srikanth 55 M 26 No No 10 - 26 97 120/70 88 114 51 No 
46 Murali 36 M 8 Yes  Yes 10 - 18 77 100/70 133 100 45 No 
47 Muthu Kumar 39 M 9 Yes Yes 9 - 29.3 114 120/80 97 76 39 No 
48 ChellaPandian 38 M 9 No No 8 - 24.1 103 120/80 83 143 30 No 
49 David 30 M 8 Yes Yes 6 - 18.3 85 130/90 100 117 43 No 
50 Gajendran 43 M 16 Yes No  24 - 17.7 88 140/90 126 138 42 No 
51 Raja 31 M 7 No Yes 15 DM,HT 17.5 85 110/80 103 117 45 No 
52 Ramachandran 37 M 8 No No 9 - 26.3 99 120/80 109 80 33 Yes 
53 Sadhasivam 47 M 11 Yes Yes 17 HT 23.2 88 130/70 105 144 54 No 
54 Subash 46 M 10 No No  28 - 17.9 86 130/70 96 129 43 No 
55 Nagarajan 33 M 6 No No  23 - 16.9 90 120/80 138 132 46 No 
56 Babu 55 M 20 No No  7 - 31 102 110/70 146 108 30 Yes 
                                           
S. 
No 
Name Age 
(yrs) 
Gen
der 
Duration 
of service 
(yrs) 
H/O 
smok
ing 
H/O 
Alcohol 
intake 
PSS 
10 
score 
Taking 
RX  for 
DM,HT 
HTG 
BMI 
kg/m
2
 
Waist  
cm 
 
B.P 
mmHg 
FBS 
mg/dl 
S.TGL 
mg/dl 
S.HDL 
mg/dl 
Presence of 
metabolic 
syndrome 
57 Devaraj 35 M 7 Yes Yes 27 - 24.4 80 120/80 125 159 52 No 
58 Kumar 41 M 21 Yes No 24 DM 29.8 103 160/110 138 92 39 Yes 
59 Kumaresan 49 M 13 No Yes 8 - 18.4 85 120/70 91 133 27 No 
60 Mani 39 M 11 Yes Yes 14 HT,HTG 19.5 92 140/90 103 82 42 Yes 
61 Manickam 51 M 31 No Yes 9 - 17 85 120/70 277 106 42 No 
62 Bakiyanathan 58 M 31 No No 24 DM,HT 27 95 140/100 129 153 33 Yes 
63 Radha Krishnan 50 M 24 Yes Yes 12 - 26.6 91 130/90 96 139 46 No  
64 Radha Krishnan 37 M 6 No No  16 - 18.4 75 140/90 116 130 46 No 
65 Selvaraj 37 M 5 No No  11 HT 23.2 88 130/70 105 144 54 No 
66 Soundararajan 52 M 22 Yes  Yes 14 DM,HT 25.4 98 140/90 95 393 45 Yes 
67 Palanisamy 52 M 30 Yes No  25 HT 30.6 96 130/90 71 126 33 Yes 
68 Palanisamy 36 M 7 Yes No  15 - 17.9 91 120/70 87 141 36 No 
69 PaneerPandi 30 M 6 Yes No 22 - 25.3 97 100/70 80 63 29 No 
70 Perumal 39 M 28 Yes No  17 DM 18.3 79 120/70 92 75 37 No 
71 Chandramohan 52 M 32 Yes Yes 20 DM 28.7 90 100/90 187 94 36 Yes 
72 Devaraj 56 M 28 No No  7 - 18 92 100/70 96 103 30 No 
73 Govindammal 35 M 7 Yes Yes 9 - 30.3 112 130/90 114 79 30 Yes 
74 Jothimanickam 31 M 6 No Yes 17 HT 28.7 85 110/70 98 144 27 No 
75 Manickan 33 M 9 No Yes 7 - 17.6 75 140/90 116 130 46 No 
76 Dhandabani 46 M 31 Yes No  10 - 31.3 108 130/80 141 132 33 Yes 
77 Selvaraj 44 M 18 No No  23 HTG 20.5 88 120/80 71 123 39 No 
78 Balakrishnan 55 M 35 No Yes 16 - 35.7 117 120/90 125 38 36 Yes 
79 Chandran 47 M 25 Yes Yes 10 DM 26.8 97 120/80 143 123 21 Yes 
80 Edwin raj 30 M 9 No Yes 9 - 18.3 76 120/70 105 142 38 No 
81 Lakshmanan 40 M 13 No No  14 - 24.7 94 120/70 95 90 27 No 
82 Muthukumar 44 M 14 No No  13 HT 27.7 98 130/90 94 114 42 No 
83 Nagarajan 34 M 7 No No 17 DM,HT 30.4 98 100/70 114 243 33 Yes 
84 Padmanaban 39 M 8 No No  12 HT 23.2 88 120/70 105 120 54 No 
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syndrome 
85 Thangarajan 50 M 23 No No  6 - 25 96 110/80 103 86 38 No 
86 Sasikumar 38 M 6 No Yes 15 - 18.2 91 120/70 89 117 40 No 
87 Sethuraman 42 M 11 No No  29 - 24.7 94 130/90 91 98 41 No 
88 Sheik mohammed 34 M 9 No No 13 - 17.6 98 120/80 105 138 50 No 
89 Srinivasan 32 M 9 No No  12 DM,HT 18.4 88 110/70 90 130 48 No 
90 Kumar 58 M 33 No No 27 - 26.4 90 130/90 120 126 36 Yes 
91 Sekar 48 M 28 No No  18 - 34.8 107 190/120 76 113 45 No 
92 Tamil Selvan 57 M 13 Yes No  20 - 21.7 89 110/80 109 130 40 No 
93 Asokan 53 M 27 No No  9 - 18.2 84 120/80 83 102 42 No 
94 Balagopalan 50 M 31 Yes No 28 DM 25.2 90 110/70 212 369 48 Yes 
95 DavidRajan 30 M 7 Yes Yes 15 - 17.9 91 100/70 96 157 46 No 
96 Deepan 45 M 17 No No  11 - 24.3 86 120/80 79 78 30 No 
97 Ganesamoorthy 45 M 13 No No 19 - 18.1 84 120/80 83 102 42 No 
98 Nagendran 54 M 26 Yes No 17 - 17.6 94 120/80 109 125 38 No 
99 Velmurugan 31 M 5 No No 12 - 27.6 95 120/80 90 91 32 No 
100 Nirmal 39 M 8 Yes No  10 DM 18 76 120/70 105 142 38 No 
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